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CHAPTER 
INTRODUCTION AND AIMS OF THE THESIS 
Chapter 1 
1.1 General introduction 
In this chapter we summarize the present knowledge about the cytokine tumor necrosis 
factor-alpha (TNFa). This precedes the first chapters of this thesis, which deal with the 
immunomodulatory effect of exposure to a single dose of TNFa by an isolated limb per-
fusion in patients with extremity tumors (chapter 2-4), or to repeated doses of TNFa in 
patients with mesothelioma (chapter 5). In the second part of this chapter the influence 
of cytokines on the ongoing acute phase response is described. This is an introduction 
to chapter 4-6. Finally the aims of this thesis are formulated. 
1.2 Tumor necrosis factor-alpha 
1.2.1 History of TNFa 
The history of tumor necrosis factor-alpha (TNFa) started in 1893, the year that William 
Coley observed that patients with streptococcal infections sometimes developed a partial 
remission of some malignancies. 1 In 1944 bacterial lipopolysaccharide (LPS) was demon-
strated as the active factor that induced hemorrhagic necrosis of transplantable tumors 
in mice. 2 The same group showed in 1962 that a serum factor induced in mice injected 
with LPS was responsible for hemorrhagic necrosis of tumors. 3 This factor was named 
tumor necrosis factor by Carswell eta!. in 1975.4 They characterized the induced factor 
in the serum of bacillus Calmette Guerin (BCG)- infected mice treated with endotoxin. 
Because of high expectations to TNF as an antitumor agent great effort in many 
laboratories led to its purification, cloning and expression. 5.9 
The availability of pure recombinant TNF in large quantities allowed detailed examina-
tions of its biological properties. TNF was found to be involved in many biological 
processes, e.g. host defense against infection, cachexia10'11 , septic shock and its 
anti-tumor effect was confirmed. 
1.2.2 Characteristics of TNFa 
TNF is predominantly produced by activated macrophages/monocytes12-14 and to a less 
extent by other cell types such as lymphocytes15, fibroblasts and epithelial cells16 induced 
by a variety of stimuli. 
TNFa circulates as a dimer or trimer of 17kDa subunits. It is synthesized as a extra-cel-
lular membrane associated 26 kDa precursor protein that is further cleaved by a micro-
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somal metalloproteinase called TNF-alpha converting enzyme (TACE) to yield the solu-
ble 17 kDa form. 17-19 In its active form TNFa contains 157 amino acids. The genes 
responsible for TNFa are contained on chromosome 6 in man, within genes of the major 
histocompatibility complex. 20•21 
The circulating half-life of TNFa is 15-30 min. 22-24 Clearance of TNFa predominantly 
takes place in the kidney, followed by the liver. 25 
TNFa mediates its activity by binding to specific receptors on the surface of cells. Two 
distinct TNF-receptors have been identified respectively with a molecular mass of 55 kDa 
(TNF-R55) and 75 kDa (TNF-R75)_ Proteolytic cleavage of these membrane-bound TNF-
receptors results in soluble TNF-receptors. 26•27 These soluble TNF-receptors compete 
with the membrane receptors for binding of free TNFa and may therefore have physio-
logic importance for the regulation of TNF-activity.28 
Besides the role of inactivation of TNFa the soluble TNF-receptors are also held respon-
sible for the clearance of TNFa. 25 
1.2.3 In vitro effects of TNFa 
Early in vitro studies suggested a selective cytotoxic and cytostatic effect for TNFa both 
in vitro and in vivo. The cytotoxic effect of TNFa was tested on a variety of tumor cell 
lines. 29-32 From these studies it became clear that the effect of TNFa on tumor cell-lines 
can be growth-stimulatory, cytostatic (growth inhibitory} or cytotoxic. Further investiga-
tions showed that the antiproliferative effect of TNFa is not limited to tumor cells, 
normal cells can also be inhibited by TNFa. Several mechanisms seemed to be involved 
in TNF-cytotoxicity.33 
1.2.4 In vivo effects of TNFa 
The murine Meth A sarcoma was the first tumor in which the antitumor effect of TNFa 
was shown.4,34·35 The anti-tumor effect, as a hemorrhagic necrosis, was evident within 
a few hours. Histological evaluation of the hemorrhagic tumor necrosis in murine tumor 
models suggested a vascular effect of TNFa on the tumor vessels_ 36•37 Other studies tried 
to specify the mechanism of the endothelial and vascular destruction caused by TNFa. 
The effect of TNFa on proliferation of endothelial cells in mice was shown to be depen-
dent of its local tissue concentration. Low doses (0.01-1.0 ng} of subcutaneous mouse 
recombinant TNF induced angiogenesis, whereas high doses (1-5 ~g) caused inhibition 
and can even induce destruction of newly formed blood vessels. 38 Tumor associated 
vasculature showed an enhanced sensitivity for these effects of TNF compared to normal 
vessels. 39.4° 
9 
Chapter 1 
TNF-induced endothelial cell damage leads to release of von Willebrand factor (VWF).41 
Release of VWF was followed by platelet aggregation and erythrostasis, which results in 
an impaired blood flow. The impaired blood flow leads to edema, hyperemia, vascular 
congestion, extravasation of erythrocytes, infiltration of polymorphonuclear neutrophils 
and hemorrhagic necrosis. 36.42-46 
The importance of the vascular effect of TNFa in the tumor is confirmed by the fact that 
it has its major effect on larger tumors, with well-developed vasculature, in contrast to 
small tumors with a poorly developed capillary bed.47.49 
1.2.5 Clinical studies with TNFa 
Systemic administration 
Phase I clinical studies in cancer patients were designed to determine the maximum 
tolerated dose, pharmacokinetics and toxicity of TNFa. 
Systemic application of TNFa was limited by unacceptable side-effects, such as hypoten-
sion and organ failure. The maximum tolerated dose (MTD) of 400 ~-tg/m2 was not able 
to produce real antitumor effect. 50.56 Results of phase II trials, determining drug effec-
tiveness, were very disappointing. No antitumor effect was observed and treatment with 
TNFa caused serious toxicity.57·61 
Intratumoral administration 
To avoid systemic toxicity locoregional treatment with TNFa has been tried to achieve 
tumor exposure to higher TNF concentrations without increasing toxic side-effects. 
Intratumoral injection of TNFa was not successful: in superficial tumors there was tumor 
regression, but in deep-seated tumors (pancreas- and hepatocellular cancer and 1 
metastatic liver tumor) it resulted in stable disease. 62 In another study 5 out of 14 patients 
with different advanced solid tumors intratumoral injection of TNFa resulted in a short-
lived local tumor regression, implying a rapid development of resistance to recombinant 
TNFa application. 63 For hepatic metastases 53% stable disease was observed without 
any responses. 64 Better results were observed in Kaposi sarcoma: 94% tumor regression, 
19% complete response.65 Intratumoral administration of TNFa had the same toxicity 
profile as subcutaneous and intravenous administration of TNFa, caused by leakage from 
the tumor to the systemic circulation.63 
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Intracavitary administration 
Intraperitoneal administration of TNFa in gynaecological cancer had no tumor regressive 
effect, but surprisingly it led to disappearance of ascites. 66•67 Abdominal pain was dose-
limiting. 68•69 Disappointing was the observation that intraperitoneal administration of 
TNFa stimulated micro-metastatic implantation in the peritoneum in intraperitoneal 
human xenograft models. 70 
Intrapleural administration in patients with malignant pleural effusion resulted in 50% of 
the patients in resolution of pleural fluid. 66 This effect was also observed in a phase I 
study of our group, in which the effects of intrapleural administration of TNFa in patients 
with malignant pleural mesothelioma was studied (chapter 5 of this thesis). 71 
Intravesical administration of TNFa in patients with superficial carcinoma of the bladder 
was well tolerated72 '73 and resulted in a complete response in 4 out of the 15 evaluable 
patients (26%).74 
Intra-arterial infusion 
Intra-arterial infusion of TNFa has been used in the treatment of liver metastasis and 
brain tumors. In hepatic arterial infusion an MTD of 150 [!g/m2 could be achieved. Dose-
limiting was severe hypophosphatemia. 75 This MTD was still far from the effective dose. 
Objective tumor response (partial response) was observed in 2 out of 14 patients with 
colorectalliver metastasis and 3 patients had a minor response. 76 
Treatment of 20 patients with malignant glioma with intra-arterial injection of TNFa led 
to 30% objective tumor regression in the group of 10 evaluable patients. In 15 out of 
the 20 patients some tumor necrosis was observed. The treatment was well tolerated. 77 
Isolated limb perfusion 
In 1988 Lejeune and Lienard at the Institut Jules Bordet in Brussels pioneered the idea 
to use TNFa in the isolated limb perfusion system for the treatment of regionally 
advanced melanoma and sarcoma. 78 The technique of isolated limb perfusion (ILP) was 
already an established method in the treatment of in transit metastasized melanoma. 79 
With this technique the intravascular concentration of TNFa could be dramatically 
increased because the ILP system is leakage free and most of the agent is washed out 
from the limb at the end of the perfusion. ILP with TNFa alone (9 patients) resulted in 
2 complete responses (CR), that lasted for 7 months and for other 4 cases a short-lived 
response: 3 partial responses (PR) and 1 minor response (MR), 3 patients had no 
response. 78•80 
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Since preclinical studies showed a synergistic effect of TNFa with interferon-gamma 
(IFNy)81-83 and with alkylating chemotherapeutic drugs84-87 , a combination triple drug 
regimen of TNFa plus melphalan and IFNy was developed. Additionally, ILP was 
performed under hyperthermia (40°C). An enhancement of the cytolytic activity of 
TNFa by hyperthermia has been demonstrated both in vitro88 and in vivo89·90 . This 
regimen used for ILP of extremity melanoma resulted in a 100% overall response and a 
90% complete response rate (CR).91-93 In patients with locally advanced sarcoma treated 
with ILP a major tumor response was seen in 82-92% of patients and made the sarco-
mas resectable in most cases after perfusion with TNF and melphalan and IFNy94 or with-
out IFNy. 95-97 Final outcome was 28-38% CR, 54-57% PR and 8-22% no change. Limb 
salvage was achieved in 82-85% of the patients.94-96·98•99 Independent review committees 
of the registration file of TNF concluded that in some patients an ILP had not been 
strictly necessary. Still in 196 patients without any other option it was concluded that 
limb salvage was achieved in 71% due to a TNF-based ILP. 97 These significant thera-
peutic improvements have recently resulted in the approval of TNF by the European 
Medicine Evaluation Agency (EMEA) for advanced sarcomas (Eggermont, 1999). 
The isolated limb perfusion system was used as a model to developing new treatment 
strategies. 100 Because a number of organs can be perfused in a similar fashion isolated 
lung101·102 , liver103•104 and kidnel05•106 perfusion models has been developed in animals 
and also phase I-II trials. Especially for isolated liver perfusion promising results had been 
attained with response rates of about 70% in patients with colorectal hepatic metastasis 
and primary malignant liver tumors. 107-110 To reduce the surgical stress (caused by laparo-
tomy to isolate the liver from the systemic circulation) an isolated hypoxic hepatic 
perfusion using balloon catheters was developed. Using this method makes laparotomy 
unnecessary. 108•111•112 The most recent developments are the application of TNFa-
mutants (that have retained antitumor activity with less toxicity) and encapsulation of 
TNFa into liposomes which augmented accumulation in tumor tissue. 113-115 
1.3 Cytokines and the acute phase response 
1.3.1 The acute phase response 
The acute phase response (APR) is the answer of the organism to disturbances of its 
homeostasis due to infection, tissue injury, neoplastic growth or immunological disorders. 
It consists of a local reaction at the site of injury characterized by a number of responses 
such as aggregation of platelets and clot formation, dilation and leakage of blood 
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vessels, and an accumulation and activation of granulocytes and mononuclear cells. 
These cells are responsible for the release of acute phase cytokines. These mediators act 
on specific receptors on different target cells leading to a systemic reaction characterized 
by (among others) fever, leukocytosis, thrombocytosis, anorexia, increases in secretion of 
glucocorticoids and dramatic changes in the concentration of some plasma proteins. 
These proteins are named acute phase proteins (APPs). 
1.3.2 History of the acute phase response 
The earliest description of the APR came from the ancient Greeks (cited by Fahraeus).116 
They already observed an increased sedimentation rate of erythrocytes in blood of 
severely ill patients. As was discovered later, this increase is due to elevated plasma 
concentrations of fibrinogen and other APPsY7•118 With the discovery of C-reactive 
protein (CRP)119 the search for other acute phase proteins was started. In 1951 Miller et 
a!. showed that the liver is the major organ for the synthesis of acute phase proteins. 120 
The fact that the synthesis of APPs takes place in the liver and injury to another part of 
the body results in an increase of APPs, led to the search for hormone-like mediators. 
Thirty years later a monocyte-derived polypeptide was described, which was involved in 
the regulation of APP-synthesis. 121'122 They named this polypeptide hepatocyte-stimu-
lating factor (HSF). HSF was later shown to be identical with interferon-j32, B cell 
stimulatory factor-2 and hybridoma plasmacytoma growth factor and was named 
IL-6. 123·124 The production of HSF by human monocytes was found to be regulated by 
lipo-polysaccharide. 125 Since TNFa and IL-l were also released by monocytes after 
exposure to lipopolysaccharide, these cytokines were also investigated for their capacity 
to stimulate the liver to production of acute phase proteins. 126.129 They were found to 
stimulate production of a subset of APPs (see below). 
1.3.3 Definition of acute phase proteins 
An acute phase protein has been defined as a protein whose plasma concentration 
increases (positive APPs) or decreases (negative APPs) by at least 25% during inflamma-
tory disorders. 130 The APR follows a sequential pattern with changes in APPs varying in 
moment and size of increase. Within the first 24 hours CRP and serum amyloid A (SAA) 
increase with a magnitude of 1000-fold the initial value. This first wave is followed by a 
slower one including APPs like a 1-acid glycoprotein, a 1-antitrypsin and fibrinogen. 
These APPs increase modestly till about 50% over the initial value (Figure 1). 131 
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Fig.l Sequential acute phase protein patterns following an inflammatory stimulus. 
From ref.131. 
The acute phase proteins can be divided in 2 subgroups according to the cytokine sub-
sets that regulate APP synthesis in vitro (Table 1).132.134 Type I APPs are induced by 
IL-l type cytokines (TNFa and f3 and IL-la and (3) and include CRP, SAA, complement 
factor C3 and al-acid glycoprotein. 135•136 Type II APPs, including fibrinogen, haptoglo-
bin, a !-antitrypsin, a 1-antichymotrypsin and ceruloplasmin were produced in response 
to the IL-6 family of cytokines (IL-6, leukemia inhibitory factor, IL-11, oncostatin M and 
ciliary neurotrophic factor. 137-140 The IL-l type cytokines are synergized by IL-6 in the 
regulation of type I APPs. So, IL-6 stimulates the full spectrum of APPs in primary 
human hepatocytes in vitro. 129 The synthesis of the negative APPs (albumin, transferrin, 
alpha-fetoprotein and a2-HS glycoprotein) is inhibited by both IL-l and IL-6 type 
cytokines in vitro. 129'135'141 
This classification is completely based on in vitro studies. Therefore the effect of combi-
nations of cytokines on human hepatoma cell lines has been studied. 141.143 It was con-
cluded that cytokines could have an additive, inhibitory or synergistic effect on each 
other. From clinical studies in cancer patients it became clear that in vivo hepatocytes are 
exposed to a mixture of cytokines, rather than to individual mediators. 144' 146 Cytokines 
operate both as a cascade and as a network in stimulating the production of APPs. 
14 
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Table 1. Classification and regulation of acute phase proteins, based on in vitro studies 
APP classification 
Positive APP 
Type I APP 
Type II APP 
Negative APP 
APP 
C-reactive protein 
Serum amyloid A 
a 1- acid glycoprotein 
complement C3 
a 1-antitrypsin 
a 1-antichymotrypsin 
fibrinogen 
haptoglobin 
hemopexin 
ceruloplasmin 
Albumin 
Transferrin 
a-fetoprotein 
a2-HS glycoprotein 
Regulation 
IL-l type cytokines: 
IL-la and~ 
TNFa and~ 
Potentiated by: 
IL-6 type cytokines 
Glucocorticoids 
IL-6 type cytokines: 
IL-6, IL-11, leukemia 
inhibitory factor, 
ciliary neurotrophic factor, 
oncostatin M 
Potentiated by: 
Glucocorticoids 
IL-l and IL-6 type cytokines 
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1.3.4 Regulation of the acute phase response 
The cytokines that are produced during inflammatory processes are the chief stimulators 
of the production of APPs. These inflammation associated cytokines include IL-6, IL-1[3, 
TNFa, IFNy and transforming growth factor-f) (TGFf3). 147-150 The most important sources 
of these cytokines are monocytes and macrophages at inflammatory sites. IL-6 is the 
major regulator of the production of most APPs, whereas the other implicated cytokines 
influence subgroups of APPs. 
Regulation of APP-synthesis occurs mainly by transcriptional contro1. 132·134•151•152 Post-
transcriptional mechanisms may also participate. 153·154 Besides cytokines also other 
factors influence the APR. Glucocorticoids generally enhance the stimulatory effects of 
cytokines on the production of APPs. 127•134•155 Additionally glucocorticoids play an 
important role in the counterregulation of the inflammatory response by inhibition of 
cytokine-production (see below). Several other hormones like insulin, thyroxin and 
human growth hormone modulate the effects of cytokines on the production of some 
APPs. 134•156' 158 Thus, the regulation of the APR is very complex, involving cooperative 
action of several mediators of the synthesis of APPs at different levels. 
The majority of studies have concentrated on examination of the mechanisms of initia-
tion and propagation of the APR. Regarding the termination of the APR little is known. 
One might not necessarily expect an inhibitory mechanism to be required because of the 
short half-life of many of the cytokines involved in the APR. The process would be turned 
off by extinction of the initiation-mediators. 
However much more mediators could be involved in the resolution of the APR (table 2). 
For instance, excess of pro-inflammatory cytokines are removed by soluble cytokine 
receptors (like soluble TNF-receptors) and receptor antagonists (such as IL-l receptor 
antagonist). 159·16° Furthermore, synthesis of proinflammatory mediators and cytokines 
can be blocked by glucocorticoids161•162 , some non-steroidal anti-inflammatory drugs 
(suppressing cyclooxygenase) and by specific inhibitors of cytokine induction162 . In addi-
tion inhibitory functions for some cytokines, including IL-4 and IL-10 have been 
described. 134 Finally, an anti-inflammatory and immunosuppressive effect was suggested 
for IL-6 and some of the IL-6 regulated APPs.163•164 IL-6 was found to moderate levels 
of TNFa and IL-l, to induce glucocorticoid release and soluble TNF-receptors and IL-l 
receptor antagonists. IL-6 regulated APPs were shown to induce IL-l receptor 
antagonist synthesis. 
16 
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Table 2. Resolution of the APR 
Resolution of the APR 
• Short half-life of initiating cytokines [162] 
• Production of anti-inflammatory cytokines (IL-4, IL-10) [134] 
• Removal of pro-inflammatory cytokines by soluble 
cytokine-receptors and receptor-antagonists [159, 160] 
• Synthesis of pro-inflammatory mediators blocked by glucocorticoids, 
NSA!Ds, specific inhibitors cytokine-induction [161, 162] 
• Anti-inflammatory and immunosuppressive effect of IL-6 and 
some IL-6 regulated APPs [163, 164] 
Normally, the APR subsides within 24-48 hours and after a few days the organism 
returns to normal function. However, the APR can be prolonged and converted in a 
chronic phase of inflammation. The mechanism of conversion from APR to chronic 
inflammation is still poorly understood. 165'166 One of the aims of this thesis is to get more 
insight in the role of the APR in chronic inflammation (chapter 4 & 6). 
1.3.5 Interferon-alpha and the acute phase response 
The interferons (IFNs) had been discovered in 195 7 by Isaacs and Lindenmann. 167 They 
observed that chick chorioallantoic membranes incubated with a heat-inactivated 
influenza virus produced a substance called IFN. This substance was found to cause 
resistance to infection by live virus. 168 Further investigations pointed out that there were 
different IFN-proteins: type I consists of IFNa and IFNB and type II represents IFNy. IFNs 
bind to specific cell surface receptors as the first step in the expression of their 
biological activity. Because IFNa and IFNB share components of the same receptor, they 
are named type I IFNs. IFNy uses a separate receptor system and is referred to as a type 
II IFN.169,17o 
Under normal conditions IFNa is not detectable in the systemic circulation. 171:172 
Contrary to many other cytokines type I IFNs can be produced by nearly all sorts of 
cells. 173·174 Production of IFNa is mostly induced by viral infectionY5-177 Viral structures 
were shown to interact with intracellular signalling pathways to induce expression of the 
type I IFNs. 178 IFNs play a dominant role in nonspecific inhibition of virus 
replication. 173,179,180 
Further investigations showed that besides its antiviral effect IFNa had also an antitumor 
effect in experimental tumors. 181 ·182 After its cloning in 1981 large quantities of 
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recombinant IFNa became available, facilitating the evaluation of the various properties 
of IFNa. 183.185 IFNa was the first cytokine that was cloned. In addition to its effects in 
viral diseases and malignancies IFNa was also found to be effective in the treatment of 
inflammatory, fibrotic and angiogenic diseases. 186 
IFNa and cytokine-response 
It was suggested that some of the therapeutic and toxic effects of IFNa might be caused 
by the induction or inhibition of other cytokines. In vitro experiments showed that IFNa 
mainly has a stimulatory effect on the production of other cytokines like IL -1, IL -6 and 
TNFa.187 
Only one study described the effect on other cytokines of a single dose of IFNa in healthy 
men. 188 All other studies are more complex because of the effect of the disease treated 
by IFNa, Corssmit et a!. found pro-inflammatory effects as well as anti-inflammatory 
effects of IFN-alpha within the cytokine network: IFNa induced release of the pro-inflam-
matory cytokines IL-6 and IL-8 and of the anti-inflammatory cytokine IL-10 and of the 
soluble TNF receptors p55 and p75. 188·189 Concentrations of TNFa and IL-l remained 
below the detection limit. 
In patients with chronic hepatitis C IFNa induced production of IL-6 by peripheral blood 
mononuclear cells (PBMC), regulated at messenger RNA level. TNFa and IL-l~ were not 
elevated.189.191 Chronic administration of IFNa during 6 months resulted in a decrease of 
IL-6 levels in complete responders and an increase in partial and non-responders. 192 Pre-
and post-treatment levels of IL-6 were higher in hepatitis patients compared to healthy 
controls, indicating that both viral-induced inflammation and treatment with IFNa influ-
enced IL-6 concentrations. In Behcet's disease IFNa brought about a decrease in levels 
of TNFa, which were elevated before treatment, without changing IL-2 levels (not 
elevated before treatment). 193 The patients experienced also clinical improvement, 
indicating that the decrease in TNFa most possibly was caused by the diminution in 
disease-activity. So, IFNa seems to induce both pro- and anti-inflammatory cytokines 
indicating a complex role within the cytokine network. 
IFNa and acute phase proteins 
In vitro studies describing the effect of IFNa on acute phase proteins could not be found. 
In healthy persons IFNa induced a decrease in the serum iron concentration and trans-
ferrin saturation with a concomitant increase in ferritin. 194 CRP remained below 
detection limit. 189·194 
18 
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In some patient groups treated with IFNa besides clinical evaluation also parameters of 
the APR were measured. Treatment with IFNa in patients with rheumatoid arthritis 
resulted in a significant improvement in the patients' joint score, in CRP-levels and 
platelet count. 195 In patients with chronic active Crohn's disease administration of IFNa 
did not show any beneficial effect on IL-6 or APP-levels and on endoscopic activity. 196 
Finally, a case-report was published describing a patient with chronic hepatitis C and liver 
hemosiderosis who was treated with long term IFNa-therapy. At the beginning of the 
treatment an increase of ferritin was observed, followed by a decrease most possibly due 
to improvement of the clinical situation. 197 From these studies it can be concluded that 
IFNa seemed to have a stimulatory effect on ferritin-levels, without affecting other APPs. 
In chapter 6 this conclusion was tested in melanoma-patients treated with IFNa. 
1.4 Aims and outline of the thesis 
Patients who underwent ILP with TNFa and melphalan enabled us in a unique way to 
investigate effects of administration of TNFa on the immune response in humans. In 
this thesis the in vivo effects on the inflammatory response and immunologic homeo-
stasis mechanisms are discribed. Effects on various components of the immune system: 
effects on immune cells, secondary cytokine responses- and kinetics of the acute phase 
reaction in response to TNFa are described and discussed. Long-term effects of TNFa 
and IFNa on the immune response were determined in mesothelioma-patients treated 
with repeated intrapleural administration of TNFa and in patients with melanoma who 
were treated with IFNa. The goal of these endeavours is to obtain a better understanding 
of how to use TNF best with regards to the TNF-associated toxicity, that so far has 
greatly limited its role in the clinical setting, how to overcome these limitations and 
create the possibility to utilize TNF in additional ways in the treatment of cancer patients. 
In chapter 2 the number of monocytes and lymphocytes was investigated in response to 
systemic leakage of TNFa during and after ILP. We also determined the function of the 
remaining monocytes and lymphocytes by measuring production of cytokines after 
stimulation in whole blood cell culture. The results in ILP-patients were compared to the 
results in patients undergoing various surgical operations to study the effects of surgery 
and anaesthesia. 
In addition to these results we specified in chapter 3 the effect of TNFa on number and 
function ofT lymphocytes and the T helper 1/ T helper 2 balance. Two methods of 
determination of T cell function were compared: intracytoplasmic staining of cytokines 
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(IL-2, IL-4 and IFNy) after stimulation of cultured peripheral blood mononuclear cells and 
production of the same cytokines in the whole blood cell culture system. 
In chapter 4 the clinical course after exposure to very high systemic levels of TNFa in 
patients undergoing ILP complicated by high leakage from the perfusate was described. 
The patterns of cytokines and the acute phase response in response to high levels of 
TNFa were compared to measurements in patients who underwent ILP without 
detectable leakage. 
The effects of prolonged presence of TNFa on other cytokines and the acute phase 
response were investigated in mesothelioma-patients treated with intrapleural admini-
stration of TNFa (chapter 5). Furthermore the effects of repetitive administration of 
TNFa were determined. 
With the obtained knowledge about the APR we ended with a study of the acute phase 
response in melanoma-patients treated with prolonged administration of IFNa (chapter 
6). In this study our hypothesis that the hyperferritinaemia in patients with adult onset of 
Still's disease could be a direct effect of IFNa was tested. 
20 
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ABSTRACT 
The objective of the present study was to investigate the effects of isolated limb perfu-
sion (ILP) with tumor necrosis factor-alpha (TNFa) and melphalan in patients with can-
cer on, first, plasma levels of cytokines, second, systemic monocyte and T-lymphocyte 
distribution and third, the ability of mononuclear cells to produce cytokines upon stimu-
lation in vitro. 
Six patients undergoing an ILP were entered into the study (group 1). In addition, 
patients undergoing a major surgical operation (group 2), minor operation (group 3) as 
well as healthy volunteers (group 4) were included as a control groups. Sensitive enzyme-
linked immunosorbent assays (ELISAs) were used to measure TNFa and interleukin-6 
(IL-6) plasma levels at various time points during and after operation. Furthermore, the 
percentage of monocytes and T-lymphocytes was determined in all studied groups using 
FACScan. In addition, cytokine production upon stimulation with lipopolysaccharide 
(LPS) and combination of anti-CD3/anti-CD28 monoclonal antibodies in whole-blood 
cultures was investigated. 
Increased plasma levels of TNFa and IL-6 in patients undergoing ILP were observed, but 
only IL-6 appeared to be increased in patients treated with a major operation. No signi-
ficant fluctuations were found in the other groups studied. Concerning the number of 
monocytes, a significant decrease was observed only in patients treated with ILP. 
Furthermore, a decreased production of TNFa, IL-6 and IL-8 upon various types of stim-
ulation in vitro was found in those patients, but also after a major operation. 
In conclusion, the results of present study show increased plasma levels of cytokines in 
patients treated with ILP and major operation. Furthermore, a decrease in numbers of 
monocytes in the circulation and the ability of mononuclear cells to produce cytokines in 
vitro may be induced by administration of TNFa in ILP. Although similar results were 
found in patients treated with major operation, the underlying mechanisms of this 
phenomenon remains to be elucidated. 
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INTRODUCTION 
Isolated limb perfusion (ILP)1 with cytostatic drugs has been demonstrated to be a 
successful treatment of regionally advanced melanoma. One of the advantages of this 
treatment modality is that up to 50 times higher concentrations of cytostatic drug can be 
delivered with minimal systemic side-effects. 2 The current treatment regimen for 
regionally advanced melanoma3 and sarcoma4 consists of high dose tumor necrosis 
factor-alpha (TNFa) combined with the melphalan in condition of mild hyperthermia. 
During or after ILP, TNFa may leak from the isolated limb circuit into the circulation.· 
The effects of TNFa leakage in patients has been investigated previously . 5'6 
The aim of the present study was to investigate the effects of systemic leakage of TNFa 
during and after ILP in patients with cancer. First, the level of TNFa and the secondary 
induction of cytokines (interleukin-6) was measured in consecutive plasma samples dur-
ing and after ILP. Second, since TNFa has been reported to stimulate the adhesion of 
mononuclear cells to the vessels endothelium1·4•7•8 , possible alterations in the number of 
circulating monocytes and lymphocytes were investigated during the ILP with TNFa. 
Furthermore, the function of peripheral blood monocytes and lymphocytes was studied 
by measuring the cytokine production in vitro. Different stimuli, such as lipopolysac-
charide (LPS) and combination of anti-CD3/anti-CD28 monoclonal antibodies were used 
to stimulate cytokine production by monocytes/macrophages and T-lymphocytes, 
respectively. 9•10 To exclude effects of surgery and anaesthesia we also examined patients 
undergoing various surgical operations. 
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MATERIALS AND METHODS 
Patients and controls 
Six patients undergoing an isolated limb perfusion GLP) with TNFa and melphalan as 
treatment of malignant melanoma or sarcoma entered into this study (group 1). To inves-
tigate the effect of operation-duration and effect of anaesthesia these patients were 
compared with six patients undergoing a different operation: 3 patients were treated with 
a major abdominal operation (group 2) and 3 patients with a minor limb and/ or chest 
operation (group 3). To exclude the effect of diurnal variation on the results, blood 
samples were sequentially obtained over the day from 6 healthy volunteers (group 4). The 
demographical and clinical characteristics of the patients are summarized in Table 1. 
Table 1. Demographical and clinical data 
Patientno. Age {years) Sex Group Diagnosis Treatment Operation 
duration (h) 
1 52 M 1 Melanoma ILP 3.5 
2 63 M 1 Melanoma ILP 3.5 
3 51 F 1 Sarcoma ILP 3.5 
4 82 F 1 Sarcoma ILP 3.5 
5 82 F 1 Sarcoma ILP 3.5 
6 64 F 1 Melanoma ILP 3.5 
7 66 M 2 Strangulation Laparotomy 1 
ileus 
8 26 M 2 Hepatocellular ca. Laparotomy 3 
9 66 F 2 Ovarial ca. Secondary 1.5 
de bulking 
10 41 F 3 Sarcoma (limb) Resection 1 
11 54 M 3 Pneumonia Open lung biopsy 1.5 
12 59 M 3 Squamous cell ca. Limb amputation 1 
ILP, isolated limb perfusion; ca., carcinoma. Group 1 consists of ILP-patients. Group 2 consists of 
patients undergoing a major operation. Group 3 consists of patients undergoing a minor operation. 
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Treatment design of isolated limb perfusion 
The details of the surgical procedures have been published previously. 4 Briefly, ILP 
consisted of a 90 minutes long perfusion with 3-4 mg of recombinant human TNFa 
(Boehringer lngelheim, Germany) and 10-13 mg/1 perfusion tissue of melphalan 
(Alkeran) (Burroughs Welcome, London, UK) at mild hyperthermia (40°C). The perfusate 
was composed of a priming volume of 700-850 ml consisted of 400-500 ml blood (50% 
red blood cells, 50% plasma), 200-400 ml of 5% dextran 40 in glucose, 5% (Isodex, 
Pharmacia, Uppsala, Sweden) Haemaccel, 10-30 ml of 8.4% sodium bicarbonate and 
0.5 ml of 2500-5000 IU heparin. TNF was injected as a bolus into the arterial line 
provided limb tissue temperature was> 38°C. Melphalan was administered 30 minutes 
later at limb temperatures between 39 and 40°C. At the end of perfusion, the limb was 
washed twice with at least 1 I of Haemaccel and 1 I of 6% dextran 70 (Macrodex, 
Pharmacia, Upsala, Sweden). 
Blood samples 
Venous blood samples were collected at five time points: pre-operative (patient already 
under anaesthesia), just before ILP and 95 minutes (5 minutes after completion of the 
washout procedure at the end of the perfusion and the release of the tourniquet) and 3 
and 24 hours after the ILP. The control patients (group 2 and 3) and healthy controls 
(group 4) were sampled at the same time points. The samples were kept at room tempe-
rature and used within 7 hours. Blood (10 ml) was collected in evacuated blood collec-
tion tubes (Venoject, Terumo, Belgium) containing sodium heparin (150 USP units) and 
was used for whole blood cell culture experiments. The remaining blood was centrifuged 
and plasma was stored at -70°C for later cytokine analysis. For measuring the percen-
tage of monocytes and lymphocytes in the circulation, peripheral blood was collected in 
EDTA-tubes {Vacutainer, Becton Dickinson, France). 
Monocyte and T-lymphocytes distribution 
EDTA-blood (100 ~-tl) was stained with conjugated monoclonal antibodies: phycoerythrin 
(PE)-labeled anti-CD14 and fluorescein isothiocyanate (RTC) -labeled anti-CD3 (Becton 
Dickinson) to detect monocytes and T-lymphocytes, respectively. At the same time 
erythrocytes were removed by lysis through addition of FACS Lysing Solution to the 
tubes. After incubation for 30 minutes at 20°C and washing twice with phosphate buffer 
(PBS with 0.1% azide) the samples were analyzed with a FACScan flow cytometer 
(Becton Dickinson). The percentage of CD14+ (monocytes) and CD3+ (lymphocytes) 
cells of 5000 counted cells was calculated. 
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Whole-blood cultures 
Whole-blood cell cultures were performed in flat-bottom micro-titer plates (Nunc, 
Kamstrup Denmark). Heparinized venous blood was diluted 1:10 with Iscove's modified 
Dulbecco's medium (IMDM) supplemented with penicillin (100 U/ml), streptomycin (100 
!lg/ml) and 2-mercaptoethanol (5x10-5 M). The monocytes of diluted blood (100 Ill) were 
stimulated with 4 or 62 pg/ml LPS (lipopolysaccharide, Escherichia coli, Sigma, 
St.Louis, MO, USA). To stimulate T-lymphocytes combination of anti-CD3 (1 !lg/ml) and 
anti-CD28 (5 !!g/ml) was added to the cultures. Incubation of the whole-blood cell 
cultures was performed at 37°C in a humidified atmosphere of 5% carbon dioxide in air. 
After 16 and 72 hours of incubation with LPS or anti-CD3/anti-CD28 respectively, the 
supernatant was harvested and stored at -70°C until cytokine analysis was performed. 
Cytokine assays 
IL-6. Levels of IL-6 were measured using enzyme linked immunosorbent assay (ELISA) 
as described previously 11 and expressed in pg/ml. Briefly, flat bottomed microliter plates 
were coated over night with purified monoclonal antibody (mAb) against IL-6 (CLB-
IL6/16). After washing, serial dilutions of IL-6-containing samples were added. Bound 
IL-6 was detected by biotinylated affinity-purified polyclonal sheep anti-IL-6. The lower 
detection level of this assay was 1 pg/ml and normal healthy controls were below 10 
pg/ml. 
IL-8. IL-8 was measured by ELISA as described previously. 12 Briefly, a coat of CLB-
IL8/1 mAb was applied overnight at a concentration of 1 f!g/ml and bound IL-8 was 
detected by biotinylated affinity-purified polyclonal sheep anti-IL-8, also at 1 f!g/ml. The 
lower detection limit of this ELISA was about 5 pg/ml of serum. Values of IL-8 for 
healthy controls determined with this ELISA were below 20 pg/ml. 
TNFa. The TNFa-specific ELISA was described earlier. 13 Flat-bottomed 96-wells plates 
were coated with mAb (18b) anti-hu-TNFa (Hoffman-La Roche, Basel, Switzerland). 
Biotinylated sheep anti-TNFa was used as a second step. The detection limit of the assay 
was 10 pg/ml. 
Statistics 
The two-sample Wilcoxon test for unpaired data was used to analyze the differences 
between groups. 
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RESULTS 
Cytokine plasma levels 
At the time point 95 minutes after the perfusion, patients treated with ILP (group 1) 
showed a significant {p<0.001) increase in plasma TNFa, which returned to pre-
operation value 3 hours post-operatively (Figure 1). No measurable TNFa was detected 
in the other studied groups. Concerning IL-6, the highest levels were measured 95 min-
utes and 3 hours after operation for group 2 and 1, respectively (Figure 1). Patients of 
group 3 and 4 had no measurable plasma IL-6 (data not shown). 
Monocytes and T-lymphocytes distribution 
At time points 95 minutes and 3 hours after ILP {group 1) a significant lower percent-
age of monocytes {p<0.05) were found in comparison with the pre-operative value 
{Figure 2A). At day 1 the percentages of monocytes in blood samples of patients from 
group 1 returned to the pre-operative value. Furthermore, there was a tendency towards 
decreased percentage ofT-lymphocytes in the circulation but the difference as compared 
with pre-operative values did not reach significance. In the blood samples of group 2, 3 
and 4 no significant fluctuations in percentages of monocytes and lymphocytes were 
found (Figure 28). 
Whole blood cultures 
Cytokine-production by monocytes 
Decreased monocytes TNFa production after stimulation with LPS in vitro was observed 
in patients undergoing an ILP (group 1) or major operation {group 2) as compared with 
patients undergoing a minor operation (group 3) and healthy controls (group 4) (Table 
2). Three hours after operation in both group 1 and group 2, the TNFa production in 
vitro was completely depressed in comparison with pre-operative production {p<0.01). 
The next morning the ability of monocytes to produce TNFa upon stimulation with LPS 
was restored. Similar results were obtained for IL-6 production (Table 2). 
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Figure 1. Median (with range) TNFa (+) and IL-6 {•) plasma levels in (A) patients treated with iso-
lated limb perfusion (ILP) and (B) patients undergoing a major operation. 
'p<O.OOl, •• p<0.01, # p<0.05 compared with pre-operative time point. 
Pre, pre-operative; 0 min; just before perfusion; 95 min, 95 minutes after the start of perfusion/ 
operation; 3 h, 3 hours after operation; day 1, next morning. 
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Figure 2. Median (with range) percentage of peripheral blood monocytes (+) and lymphocytes (•) in 
patients treated with isolated limb perfusion (A) and healthy volunteers (B).# p<0.05 compared with 
pre-operative time point. Pre, pre-operative; 0 min; just before perfusion; 95 min, 95 minutes after 
the start of perfusion/operation; 3 h, 3 hours after operation; day 1, next morning. 
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Table 2. LPS-stimulated cytokine production (TNFa and IL-6) in whole blood cell cultures in patients 
undergoing an ILP, a minor/major operation and healthy volunteers 
TNFa (pg/ml) production upon stimulation with LPS 
ILP Major operation Minor operation Controls 
Timepoints (n=6) (n=3) (n=3) (n=7) 
LPS 4 pg/ml 
Before 426 (66-1143) 54 7 (359-865) 948 (688-2004) 757 (143-1064) 
Omin 76 (29-479). ND ND 623 (469-865) 
95 min 68 (21-682) • 371 (84-405) •t 896 (512-1481) 673 (573-959) 
3h 11 (7-241) •t 100 (62-133) *t 585 (416-1075) 817 (420-15 73) 
Day 1 77 (58-666) .• 241 (240-398) 401 (290-857) 433 (161-1650) 
LPS 62 pg/ml 
Before 569 (233-699) 736 (477-906) 835 (541-1406) 889 (369-1246) 
Omin 135 (50-206) • ND ND 946 (774-1293) 
95 min 66 (7-730). 542 (90-547) •t 982 (569-1116) 1112 (605-1263) 
3h 22 (7 -352) •t 135 (69-147) •t 502 (443-1525) 1054 (666-1515) 
Day 1 292 (107-715). 380 (326-586) 675 (293-926) 950 (313-1398) 
JL-6 (pg/ml) production upon stimulation with LPS 
ILP Major operation Minor operation Controls 
Timepoints (n=6) (n=3) (n=3) (n=7) 
LPS 4 pg/ml 
Before 1687 (247-2903 1345 (1176-1370) t 2384 (1399-2662) 1257 (333-2431) 
0 min 677 (7-1461) ND ND 1243 (741-1485) 
95min 43 (7-1280) •t 832 (295-1256) t 1886 (1623-2201) 1359 (1002-2850) 
3h 123 (53-355) *tT 537 (324-837) •t 1565 (1434-3142) 1483 (657-3037) 
Day 1 765 (235-2385) 1243 (1234-1340) 1766 (830-2924) 1307 (408-2243) 
LPS 62 pg/ml 
Before 1940 (673-3311) 1801 (1521-1992) 2469 (1476-2506) 1576 (840-1974) 
Omin 1129 (269-2051 ND ND 1511 (1145-1683) 
95 min 72 (45-1165) •t 1030 (230-1580) 1980 (1509-1998) 2048 (1151-2924) 
3h 219 (73-313) •tr 641 (285-1278) •t 1653 (1617-3598) 1506 (1427-2518) 
Day 1 2020 (738-2811) 1776 (1143-2281) 2181 (2095-3063) • 1637 (979-2220) 
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Results are expressed as median (range). LPS, lipopolysaccharide; ILP, isolated limb perfusion; time-
points: before, pre-operative; 0 min, just before perfusion; 95 min, 95 minutes after the start of per-
fusion; 3 h, 3 hours after the end of operation; day 1, next morning. • Patients compared with 
healthy control subjects {p<0.05). 
t Patients compared with patients undergoing a minor operation {p<0.05). :f: ILP-patients compared 
with patients undergoing a major operation {p<0.05). 
Cytokine production by T-/ymphocytes 
T-lymphocyte function of different groups of patients, as measured by IL-8 production 
upon stimulation with anti-CD3/anti-CD28 in vitro, is shown in Table 3. IL-8 production 
in groups 1 and 2 was significantly lower (p<O.OS) than in groups 3 and 4. Particularly 
3 hours after operation, production of IL-8 upon stimulation was hardly provoked. 
Furthermore, IL-8 production in group 3 was significantly lower (p<0.05) in comparison 
with healthy control subjects (group 4) as measured at time point 3 hours after opera-
tion. The healthy controls showed a constant production of IL-8 at different time points. 
Table 3. Cytokine production (IL-8) in whole blood cell culture after stimulation with anti-CD3/anti-
CD28 in ILP patients, patients undergoing a minor/major operation and healthy controls 
IL-8 (ng/ml) production upon stimulation with anti-CD3/anti-CD28 
ILP Major operation Minor operation Controls 
Timepoints (n=6) (n=3) (n=3) (n=7) 
Before 58 (21-270) 32 (28-33) 28 (24-96) 41 (19-286) 
0 min 26 (0.5-144) ND ND 93 (29-884) 
95 min 2.0 (0.2-30) * 21 (11-44) 24 (11-41) 37 (23-296) 
3h 0.5 (0.2-7.7) *t 2.9 (0.6-11) *t 16 (15-21) • 44 (22-190) 
Day 1 4.7 (3.4-33) * 8.0 (2.3-67) 28 (13-50) 40 (20-124) 
Results are expressed as median {range). ILP, isolated limb perfusion; timepoints: before, pre-opera-
tive; 0 min, just before perfusion; 95 min, 95 minutes after the start of perfusion; 3 h, 3 hours after 
the end of operation; day 1, next morning. • Patients compared with healthy control subjects 
(p<0.05). t Patients compared with patients undergoing a minor operation {p<0.05). 
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DISCUSSION 
In the present study the effects of ILP with TNFa were studied on the plasma cytokine 
profile (IL-6, TNFa), the number of monocytes and lymphocytes measured in the circu-
lation, as well as cytokine production (TNFa, IL-6, IL-8) ex vivo, measured by the whole 
blood cell cultures. These results were compared with patients undergoing various 
operations. Eventual diurnal effects on the results were studied by following healthy 
control subjects. 
Increased plasma-levels of TNFa and IL-6 observed in the ILP-patients were described 
previously.5•14•15 In the present study IL-6 was also increased in patients undergoing ILP 
and in patients treated with major operation. That is in accordance with the observa-
tions of Glaser et al. 16 in patients undergoing a conventional cholecystectomy, but much 
lower than described by Cruickshank et al. 17 in a study of serum IL-6 levels after surgery 
of various degrees of severity. The rise in IL-6 plasma levels in ILP-patients may be 
caused by the preceding TNF-peak. In the patients undergoing a major operation, we 
could not measure TNFa in plasma, whereas IL-6 was certainly detectable after 
operation (Figure 1). A possible explanation may be that local release of endotoxin after 
bowel handling during intra-abdominal surgery stimulates systemic release of IL-6. 17 
It has been suggested previously that systemic administration of TNFa may influence 
monocyte and T lymphocyte distribution in the circulation. 18•19 In the present study the 
greatest changes in cell-distribution were observed in patients undergoing an ILP. The 
percentage of monocytes decreased, with the maximum at 3 hours after operation, but 
rebounded to the pre-operative value within 24 hours. However, the T-lymphocytes only 
showed a tendency to decrease in comparison with the pre-operative values. These 
observations may be caused by increased margination of lymphocytes and monocytes as 
a result of their adherence to the vessel walls and/or migration into the tissues under the 
influence of the circulating cytokines.7·8•19·20 Recent observations in our patients showed 
hardly any alteration in the cell distribution in the perfusate during operation. So, 
although sequestration took place during operation, it cannot be excluded specifically in 
the perfused limb or on the total body. Since no fluctuations in cell distribution were 
observed in patients undergoing major or minor operation, the effect of surgery or 
anaesthesia on monocyte decrease in patients undergoing ILP seems less likely. 
Decrease in production of cytokines after major operation as measured by a whole blood 
cell cultures was described earlier by Pirenne et a!. 21 This is in accordance with the 
present findings in which decreased production of IL-6, TNFa and IL-8 upon stimulation 
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in vitro during and after ILP and major operation was found. However, no such effect 
was observed in patients undergoing a minor operation or in normal control subjects. 
The underlying mechanism is not completely understood. In vitro studies showed that the 
synthesis of cytokines can be blocked by corticosteroids. 22 A possible role in the observed 
effects of ILP and major operation, may be played by cortisol, since the tissue-injury (in 
patients with major operation) and leakage of TNFa (in patients with ILP) may result in 
release of cortisol. 6•21 Furthermore, the decrease in the number of monocytes, as 
observed in the present study, may also play a part in the drop in cytokine-production. 
However, by expressing the cytokine production per 1000 monocytes, a depressed IL-6 
and TNFa production was still calculated (data not shown). The shift of lymphocyte sub-
populations during operation was reported previously. 23 Relation between cortisol and 
lymphocyte number was described by Hamid et a!. 24 , where an increase in cortisol was 
followed by a decrease in the number of lymphocytes in the circulation. Decreased IL-8 
production by lymphocytes in vitro might represent a reduced function of those cells, 
since no significant decrease in the lymphocyte number during ILP and various surgical 
operations was found in the present study. 
In conclusion, this study describes the cytokine profiles after different forms of surgical 
interventions. Patients undergoing an ILP with TNFa and melphalan showed elevated 
levels of TNFa and IL-6 in the circulation. Only in this group of patients was TNFa meas-
urable in the circulation. However, in patients undergoing a major opera-tion IL-6 was 
also detected, perhaps caused by the release endotoxins during the intra-abdominal 
operation. The effects of anaesthesia and/or duration of the operation on present results 
may, to some extend, be excluded as no effects on monocyte and T-lymphocyte distri-
bution and function were found in patients treated with minor operation. During, but also 
shortly after operation, monocytes and T-lymphocytes showed a decreased ability to pro-
duce cytokines. Thus, TNFa appears to have a profound effect on T cell and monocyte 
function. This modulation remains to be elucidated. 
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ABSTRACT 
Background: The objective of the present study was to investigate the effects of isola-
ted limb perfusion (ILP) with tumor necrosis factor-alpha (TNFa) and melphalan on 
circulating T-cells from cancer patients, using two different methods. 
Patients and methods: Eight patients undergoing an ILP entered the study. At first, 
the number of T-cells at several time-points was determined using FACScan. 
Subsequently, production of interferon-gamma (IFNy) (T-helper 1) and interleukin-4 
(IL-4) (T-helper 2) was measured at the intracytoplasmic level after stimulation with phor-
bol12-myrastate 13-acetate (PMA) and ionomycin. IFNy, IL-4 and IL-2 (also T-helper 1) 
production in the whole-blood cell culture system was then determined after stimulation 
with a combination of anti-CD3/anti-CD28 monoclonal antibodies. 
Results: An enormous decrease in the number of circulating T-cells was observed. In 
the remaining T-cell population cytokine-production (IL-2, IL-4, IFNy) was depressed, 
showing the same pattern in both methods. No difference could be detected between the 
effect of TNFa and melphalan on Th1- and Th2-cells. 
Conclusions: The results demonstrate that TNFa and melphalan reduced the number 
of circulating T-cells and at the single-cell level decreased the cytokine-production in the 
remaining circulating T-cells. No selective effect of TNFa on Th1- or Th2-cells could be 
detected. If the impaired T-cell function is representative for all T-cells remaining in the 
systemic circulation, this could help to explain the tolerability of high TNF concentrations 
after ILP, perhaps by decreasing the synthesis and production ofT-cell derived cytokines. 
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INTRODUCTION 
At present, TNFa is used in the treatment of patients with cancer. The current treatment 
regimen in patients with regionally advanced melanoma and sarcoma consists of isolated 
limb perfusion (ILP) with TNFa and melphalan under mild hyperthermia.1·3 This treat-
ment enables us to study the effect of TNFa on the immune system in these patients. 
Until now, only a few studies of the effect of TNFa in normal subjects have been carried 
out. It has been shown in healthy humans that TNFa induces the release of mainly pro-
inflammatory cytokines accompanied by activation and degranulation of leukocytes. 
Lymphocyte-number was decreased by TNFa-infusion. 4 Furthermore, TNFa activates 
coagulation via the extrinsic pathway, leading to the formation of thrombin5, and fibri-
nolysis (measured by plasminogen activator (PA), u-PA, t-PA and PAI-1)6 . 
In cancer-patients treated with TNFa intravenously, stimulation ofT-cells and monocytes 
has been observed, as reflected by an increase in soluble interleukin-2 (IL-2) receptors 
and circulating neopterin respectively. 7 In another study, induction of IL-6, C-reactive 
protein (CRP) and cortisol was observed after intravenous administration of TNFa in 
cancer patients. 8 
We reported previously on the induction of the acute phase protein reaction and stimu-
lation of the immunoglobulin synthesis in cancer patients treated with an ILP with TNFa 
and melphalan. 9 Fibrinolysis was initially activated, induced by leakage of TNFa from the 
perfusion system, and was subsequently inhibited by PAI-l. 10 
The aim of our study was to investigate the effect of TNFa on circulating T-cells. Our 
main interest in this study was whether in this acute situation, i.e. in patients treated with 
TNFa intravenously, alterations in the T-helper 1 (Thl)/ T-helper 2 (Th2) balance were 
induced. This question is related to observations in patients with rheumatoid arthritis, in 
whom increased levels of TNFa and a disturbed Thl/Th2 balance have been observed.n 
To obtain insight in the Thl/Th2 balance in our ILP-patients we used two methods: 
intracytoplasmic IFNy and IL-4 staining after culturing of peripheral blood mononuclear 
cells (PBMCs) derived during and after ILP and production of these cytokines in the 
whole-blood cell culture system. 
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PATIENTS AND METHODS 
Patients and treatment 
Blood samples were obtained from patients undergoing an ILP with TNFa and melpha-
lan as a treatment for melanoma and sarcoma. Clinical and demographic characteristics 
are summarized in table 1. 
The procedure of ILP has been described previously.3 Briefly, ILP consisted of a 90 
minutes long perfusion with 3-4 mg of recombinant human TNFa (Boehringer 
lngelheim, Germany) and 10-13 mg/1 perfusion tissue of melphalan (Alkeran) 
(Burroughs Wellcome, London, UK) at mild hyperthermia (39 to 40°C}. The perfusate 
was made up of a priming volume of 700·850 ml, which consisted of 400-500 ml of 
blood (50% red blood cells, 50% plasma), 200-400 ml of 5% dextran 40 in glucose 5% 
(Isodex, Pharmacia, Uppsala, Sweden), 10-30 ml of 8.4% sodium bicarbonate and 0.5 
ml of 2500-5000 IU heparin. TNFa was injected as a bolus into the arterial line 
provided that the limb tissue temperature was > 38°C. Melphalan was administered 30 
minutes later at limb temperatures between 39 and 40°C. At the end of perfusion, the 
limb was washed with at least 2liters of 6% dextran 70 (Macrodex, Pharmacia, Uppsala, 
Sweden). During perfusion, leakage from the perfusate to the systemic circulation was 
monitored by the use of radioactive human serum albumin (injected in the perfusate) and 
a gamma-detector above the heart. 
Blood samples 
Venous blood samples were collected at five time points: pre-operative, just before ILP, 
and at 95 minutes (5 minutes after completion of the washout procedure at the end of 
perfusion and the release of the tourniquet), and 3 and 24 hours after ILP. In addition, 
three samples were taken from the perfusate: just before TNFa was added to the per-
fusate, halfway through perfusion and at the end of the perfusion (just before the 
washout). 
Blood for the whole-blood cell culture and the intracytoplasmic cytokine staining was 
collected in 10 ml evacuated blood collection tubes (Venoject, Terumo, Belgium) 
containing sodium heparin (150 USP units). For determining changes in the cell popu-
lation, blood was collected in EDTA-tubes (Vacutainer, Becton Dickinson, France). 
Cell-number and -distribution 
EDTA-blood (100 1-1l) was stained with fluorescein isothiocyanate (FITC)-labelled anti-
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CD3 (Becton Dickinson) to detect T-lymphocytes. At the same time, erythrocytes were 
removed by lysis by the addition of FACS Lysing Solution (Becton Dickinson) to the 
tubes. After incubation at 20oC and washing twice with phosphate buffered saline (PBS, 
containing 0.1 % azide), the samples were analyzed on a FACScan flowcytometer 
(Becton Dickinson). The number of leukocytes was counted on a Coulter counter. 
Intracytoplasmic cytokine production 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood by 
density separation over Percoll (Pharmacia Fine Chemicals, Uppsala, Sweden). Cell 
cultures were performed in 24-well plates (Nunc, Wiesbaden, Germany). The cells were 
cultured (1x106 PBMCs/ml) in Iscove's medium supplemented with 5% heat-inactivated 
fetal calf serum, penicillin (100 U/ml), streptomycin (100 ~-tg/ml) and 2-mercaptoethanol 
(5x10.5 M). One milliliter of PBMCs was stimulated with a combination of ionomycin 
(1 ~-tM) (Sigma, St.Louis, MO, USA) and phorbol 12-myrastate 13-acetate (PMA 1 
ng/ml) (Sigma) in the presence of monensin (1 ng/ml) (Sigma). As a negative control, 
cells were incubated without stimulation. 
After 5 hours of incubation at 37oC in a humidified atmosphere of 5% carbon dioxide in 
air, the cells were harvested, washed twice with PBS and fixed with 4% paraformal-
dehyde for 5 minutes. The cells were then washed again and incubated in PBS/0.1% 
saponin (Calbiochem, La Jolla, CA, USA)/0.5% bovine serum albumin (BSA, Boseral 
Organon Technika)/10% human pooled serum (HPS, CLB) (PBS-SBH) for 10 minutes. 
Cells were resuspended in PBS-SB (without HPS) and incubated for 30 minutes at 4 oc 
with the biotin-labeled anti-cytokine monoclonal antibodies (mAbs) - anti-IL-4 (CLB-5A4) 
and anti-IFNy (CLB-MD2)- and lgG1 as a negative control. After washing three times in 
PBS-SB, the cells were incubated with phyco-erythrin (PE)-labeled streptavidin for 20 
minutes at 4°C. The cells were then washed twice in PBS-SB and once in PBS and incu-
bated with RTC-labeled anti-CD3 to isolate the T-lymphocytes. Finally, after 30 minutes 
of incubation and after washing three times in PBS, the cells were resuspended in 150 ~-tl 
of PBS and analyzed on a FACScan flow cytometer. Stimulated cells incubated with lgG 1 
were used as negative controls. 
Whole-blood cell culture 
Whole-blood cell cultures were performed in flat-bottomed micro-titer plates (Nunc, 
Kamstrup Denmark). Heparinized blood was diluted 1:10 with Iscove's modified 
Dulbecco's medium (IMDM) supplemented with penicillin (100 U/ml), streptomycin 
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(100 f,lg/ml) and 2-mercaptoethanol (5x10-5 M). A 200 f,ll sample of the diluted blood 
was stimulated with the combination of anti-CD3 (1 f,lg/ml) and anti-CD28 (5 f,lg/ml). 
Incubation of the whole-blood cell cultures was performed at 37°C in a humidified atmos-
phere of 5% carbon dioxide in air. After 72 hours, the supernatants were harvested and 
stored at -70°C until cytokine analysis was performed. 
Cytokine assays 
IFNy. Levels of IFNy were measured using enzyme-linked immunosorbent assay (EUSA) 
as described previously with minor alterations.12 Rat-bottomed 96-well plates were 
coated with mAb anti-IFNy (CLB-MD2, 5 fA.g/ml). Biotinylated sheep anti-IFNy (CLB-
MD1, 2 f,lg/ml) was used to detect bound IFNy. The detection limit of this assay was 7 
pg/ml and values in healthy control subjects were below 10 pg/ml. 
IL-4. Levels of IL-4 were also measured using EUSA, as described previously. 13 Briefly, 
flat-bottomed micro-titer plates were coated overnight with purified mAb against IL-4 
(CLB-4F2) at a concentration of 1 f,lg/ml. After washing, serial dilutions of IL-4 con-
taining samples were added. Bound IL-4 was detected by biotinylated affinity purified 
polyclonal sheep anti-IL-4 (5A4). The lower detection level of this assay was 10 pg/ml. 
The levels in normal healthy control subjects were below 30 pg/ml. 
IL-2. The IL-2 EUSA was performed following the same procedure as described above. 
MAb CLB-B-G5 was coated over night at room temperature (2 f,lg/ml in PBS, 100 ~ 
per well) on flat-bottom micro-titer plates (Nunc, Maxisorb, Robskilde, Denmark). All sub-
sequent incubations were in 100 f,ll volumes at room temperature. After three washings 
with PBS-0.02% (v/v) Tween 20 (PT), an excess of biotinylated purified polyclonal goat 
anti-IL-2 was added in HPE buffer (High Performance EUSA buffer)-1% normal mouse 
serum (final concentration 1 f,lg/ml) at 50 f,ll per well together with 50 f,ll of IL-2 con-
taining samples followed by incubation for two hours. Plates were washed (3 x PT) and 
incubated with streptavidin-poly-horseradish peroxidase (1: 10000 diluted, CLB, 
Amsterdam, The Netherlands) in PBS for 30 minutes, washed and developed with a solu-
tion of 100 fA.g/ml of 3,5,3',5'-tetramethylbenzidine (Merck, Darmstadt, Germany) with 
0.003% H20 2 in 0.11 M sodium acetate, pH 5.5 (100 f,ll per well). The reaction was 
stopped by the addition of an equal volume of H2S04 to the wells. Plates were read at 
450 nm in a Titertek Multiscan reader (Row Laboratories, Mclean, VA). Human r!L-2 
was used as a standard curve; the detection limit was 10 pg/ml. Values in normal healthy 
control subjects were below 10 pg/ml. 
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RESULTS 
Patients 
During perfusion no leakage was detected using radioactive albumin. TNFa was 
measurable in the systemic circulation from 5 minutes till 3 hours after washout. 
Maximum TNF-levels were about 2 ng/ml (data not shown). 14 All patients developed a 
complete tumor response after treatment with ILP. 
Cell-number and -distribution 
The number ofT-cells per ml is shown in Figure 1. This number was determined from 
the percentage of CD3+ cells (measured using a FACScan), and the number of leuko-
cytes was measured on the Coulter counter. The number ofT-cells remained constant till 
the 95 minutes time-point. At 3 hours only 5% of the pre-operative number remained. 
Next morning the T-cell number had recovered somewhat to about 25% of the pre-oper-
ative value. In the perfusate, the T-cell number decreased. At the start of the perfusion, 
the median T-cell number in the perfusate was 16*104/ml, halfway through it was 57% 
and at the end of perfusion it was 39% (data not shown). 
10 . --.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.- ---------------
pre Omin 95min 3h day 1 
time 
-+-patient 1 
__._patient2 
--A--patient3 
--M--patient4 
Figure 1. Absolute number of circulating T cells pre ml in the systemic circulation. Pre, preopera-
tiue; 0 min, just before perfusion; 95 min, 95 minutes after the start of perfusion; 3 h, 3 hours after 
operation; day 1, next morning. 
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Intracytoplasmic cytokine production 
The pre-operative percentage of IFNy-producing cells was around 20-25% of 5000 
counted T-lymphocytes. Three hours after the operation, T-lymphocytes producing IFNy 
had declined to 43% (median) of the pre-operative value. On day 1 after the operation, 
the fraction of IFNy-producing T-cells was restored to 61% of the initial level (Figure 2). 
In the perfusate, T-lymphocytes positive for intracytoplasmic IFNy-production showed a 
sharp decline from a median of 23% at the start to 12% halfway through perfusion (not 
measured at the end of perfusion, data not shown). 
In all samples IL-4 was not measurable because of very low production, and was not dis-
tinguishable from the background signal. 
pre Omin 95min 
time 
3h day 1 
_._patient 1 
-patient2 
__.__patient 3 
~patient4 
Figure 2. IFNy-producing T-ee/Is in the systemic circulation expressed as a percentage of the absolute 
number of circulating T-ee/Is. 
Cytokine production in whole-blood culture 
IL-4, IFNy and IL-2-production in whole-blood culture was expressed in pg per 1000 T-
lymphocytes (Figure 3). IFNy decreased from the start of operation until it reached a level 
of 1% 3 hours after operation. On day 1 the production was still depressed in three out 
of four patients. 
After the start of the operation, IL-4 production fell to 20% at 95 minutes (5 minutes 
after the release of the tourniquet). Three hours post-operatively and on day 1, IL-4 was 
still produced at only a very low level. IL-4 in perfusate was barely measurable. 
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In addition, production of IL-2 decreased during and after the whole procedure. 
In the perfusate, cytokine production was much lower than in the systemic circulation; 
production of all cytokines showed a decrease during perfusion. 
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Figure 3. Production of (a) IFNy, (b) IL-4 and (c) IL-2 in whole-blood cell culture, expressed in pg per 
1000 T-cells in the systemic circulation 
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DISCUSSION 
In this study, we have investigated the effect of exposure to TNFa. on the Th1/Th2-
balance in cancer patients undergoing ILP with TNFa.. Cytokine-production was studied 
at the singie-celllevel by intracytoplasmic staining after cell stimulation in vitro. Further, it 
was also determined in the whole-blood cell culture system after specific T-cell stimulation. 
In our previous study on the effect of TNFa. on T-cells, we observed a decrease in the 
number of T-cells in the circulation during and after ILP. 14 We also studied specific cell 
populations using cell markers (CD4, CDS). These immunospecific cell markers disap-
peared, showing the same pattern as CD3+-cells, suggesting that the ratio between the 
different cell populations remains the same (data not shown). In the present study, to 
determine whether TNFa would affect the Th1/Th2-balance, we investigated the ability 
of the remaining T-cells to produce IFNy and IL-4. 
We measured intracellular cytokine-production using the same procedure as described 
previously. 15-17 In these studies, only 1-2% of the cells were found to be IL-4-positive. 
Also, in our cancer-patients hardly any IL-4 producing cells could be detected using this 
method. However, clear changes took place in the IFNy-producing T-lymphocytes. IFNy-
positive T-cells declined during and after ILP. Next morning the fraction of positive-stai-
ned T-lymphocytes was still somewhat depressed. In the perfusate, IFNy-producing T-cells 
also disappeared during ILP. 
The observations obtained in the intracytoplasmic studies were confirmed by determi-
nation of cytokine-production in whole blood cell culture. IFNy-production after T-cell-
stimulation in whole blood cell culture also decreased during and after ILP. At 3 hours and 
at day 1 after ILP, hardly any IFNy was measured in the supernatant. In the perfusate, 
IFNy-production was completely depressed after 90 minutes. These data were similar to 
those obtained for IL-2-production; only at 95 minutes was IFNy lower than IL-2. Next to 
IFNy, IL-4 production was also affected by TNFa.. From the start of operation until the 
next morning IL-4 fell, reaching a minimum at day 1. IL-4-production in the perfusate 
supernatants was measurable only in one patient. It also declined during perfusion. 
Our results differ from observations in vitro in which TNFa., added to human T-cells in 
vitro, stimulated growth and differentiation of T-cells, shown by an increase in TNF- and 
IL-2-receptor expression on T-cells. 18•19 The concentration of TNFa used (0.2-20 ng/ml) 
is about the same as the concentration measured in the systemic circulation of our ILP-
patients directly after ILP.14 This observation shows that the situation in vivo is much more 
complex than in vitro. A probable causal factor could be cortisol, which is secreted in 
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response to the stress of the operation. Cortisol is known to decrease cytokine-produc-
tion20·21 and the number of lymphocytes. 22 
It is clear that TNFa in the ILP-patients has a striking impact on the number of circulating 
T-cells. TNFa induces adhesion of PBMCs to the endothelium of both tumor-vessels23 and 
normal vessels. 24-26 The overall disappearance of T-cells in our patients can, in part, be 
held responsible for the decrease in IL-4, IL-2 and IFNy-production in whole-blood cell 
culture. The infusion of fluids during perfusion causes only a small intravascular dilution 
because most of the fluids go into the extravascular compartment (operation area and 
oedema). 
In the remaining circulating T-cells, TNFa also had an effect on function, as shown by the 
intracytoplasmic cytokine production after cell stimulation (Fig.2). The effect of TNFa on 
T-cells could not be restricted to a specific T-cell-population using the whole-blood cell 
culture system. IL-4 as well as IFNy and IL-2 production decreased, suggesting that both 
Thl- and Th2-cells were affected by TNFa. This could also be concluded from the results 
measured in the perfusate. If this impaired T-cell function is representative of all T-cells in 
the systemic circulation, this could be an explanation for the tolerability of high TNFa 
concentrations after ILP. This tolerability could be caused by a decrease in the synthesis 
and production of T-cell derived cytokines. 
A distinction between the effect of TNFa on cytokine-production and on cell-disappea-
rance could be made. The decrease in cytokine-production preceded the numerical drop 
in the T-cell population in the systemic circulation: at time-point 95 minutes the number 
of circulating T-lymphocytes was unchanged (Fig. I), whereas the production of cytokines 
was already diminished (Fig.3). Three hours after ILP, both cell-number and cell-function 
were depressed. An explanation for this phenomenon could be that TNFa had an effect 
on a specific population of cytokine-producing T-helper-cells. This suggestion is sustained 
by the observation in the intracytoplasmic cytokine-staining procedure: At time-point 95 
minutes IFNy-producing T-cells were reduced, illustrating that some of the cells had 
disappeared. 
In conclusion, we could not show TNFa has a selective effect on Thl- or Th2 cells. 
Overall, a strong effect was seen on the number of circulating T-cells as well as on the 
T-cell-function expressed in IFNy-production and -secretion, IL-4-production and -secre-
tion as well on IL-2-secretion. If the impaired T-cell function in the T-cells remaining in 
the blood is representative for all T-cells, this could partly explain the tolerability of high 
TNFa concentrations in the systemic circulation after ILP, perhaps by decreasing the 
synthesis and production of T-cell-derived cytokines. 
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ABSTRACT 
Background: Since the introduction of high-dose tumor necrosis factor-alpha (TNFa) in 
the setting of isolated limb perfusion (ILP) in the clinic, prevention of leakage to the body 
of the patient is monitored with great precision for fear of TNF-mediated toxicity. That 
we observed remarkably little toxicity in patients with and without leakage prompted us 
to determine patterns of cytokines and acute phase proteins in patients with high 
leakage and in patients without any leakage. 
Methods: TNFa, interleukin (IL)-6, IL-8, C-reactive protein (CRP) and secretory phos-
pholipase Az (sPLA2) were measured at several time-points during and after (until 7 days) 
ILP in 10 patients with a leakage to the systemic circulation varying in percentage from 
12 to 65%. As a control, the same measurements, both in peripheral blood and in 
perfusate, were performed in 9 patients without systemic leakage. 
Results: In patients with systemic leakage, levels of TNFa increased during ILP, 
reaching values to 277 ng/ml. IL-6 and IL-8 peaked 3 hours after ILP with values 
significantly higher compared with patients without systemic leakage. CRP and sPLA2 
peaked at day 1 in both patient groups. sPLA2 with significant higher levels and CRP, in 
contrast, with lower levels in the leakage-patients. 
Conclusions: High leakage of TNFa to the systemic circulation caused by a compli-
cated ILP led to a 10-fold to more than 100-fold increased levels of TNFa, IL-6 and 
IL-8 in comparison with patients without leakage. The increase of the acute phase 
proteins was limited. Even when high leakage occurs, this procedure should not lead to 
fatal complications. The most prominent clinical toxicity was hypotension (grade III in 4 
patients) which was easily corrected. No pulmonary or renal toxicity was observed in any 
patient. It is our experience that even in the rare event of significant leakage during a 
TNFa-based ILP, postoperative toxicity is usually mild and can be easily managed by use 
of fluid and, in some cases, vasopressors. 
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INTRODUCTION 
The technique of regional isolated limb perfusion (ILP) with the use of an extracorporeal 
circuit was pioneered by Creech and coworkers. 1 The advantage of this treatment 
modality is that high dose of cytostatic drug can be delivered to the tumor-bearing 
extremity without producing systemic side effects. ILP permits regional cytostatic 
concentrations 15 to 20 times higher than those reached after systemic administration.2 
The standard drug in this setting is melphalan (L-phenyl-alaninemustard). In patients with 
multiple melanoma in-transit metastases, an ILP with melphalan results in about 50% of 
the patients in a complete remission. 3 Addition of tumor necrosis factor-alpha (TNFa) to 
melphalan has proven most effective in terms of response rate, yielding a 80 to 90% 
complete response rate, and an overall response of about 100%.4·5 In locally advanced 
soft tissue sarcomas the use of TNFa in combination with melphalan has proven remark-
ably effective in rendering irresectable tumors resectable and thereby preventing 
amputations. 5•6 The efficacy of TNFa against the drug-resistant soft tissue sarcomas has 
led to the approval of TNFa by the EMEA (European Medicine Evaluation Agency) for 
its use in combination with melphalan.7 
In the ILP system, TNFa is administered in a 10-fold higher dose compared with the 
maximum tolerable dose in systemic administration. The maximum tolerable dose of 
TNFa in single-dose intravenous or intramuscular administration is limited by toxicity at 
400 ~-tg/m2 •8•9 Toxicity consists of fever, hypotension, chills and transient leukopenia. 
Hardly any tumor response has been reported after systemic administration of TNFa.9·11 
Despite careful precautions, systemic leakage of more than 10% appeared in 10 patients 
during the last 8 years in our hospital. These patients had a remarkably mild clinical 
course. To get more insight into the cause of this discrepancy between the high systemic 
concentration of TNFa and the mild clinical symptoms, we studied cytokine levels and 
the acute phase response. 
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PATIENTS AND METHODS 
Patients 
From the 212 patients who underwent an ILP with TNFa and melphalan in the past 8 
years in our hospital, 10 patients were selected because of very high systemic levels of 
TNFa caused by leakage from the perfusate. These patients were treated because of an 
irresectable sarcoma (n=6) or melanoma with multiple in transit metastases (n=4). 
Demographic and treatment characteristics are summarized in table 1. As a control 
group, we studied 9 comparable patients undergoing ILP without systemic leakage. 
These patients were all sarcoma-patients, who underwent a 90-minute-long ILP with 3 
to 4 mg of TNFa. The mean age was 48 years (range, 21-77 years). 
Table 1. Patient characteristics 
Duration Maximum 
Patient Age, Sex Diagnosis Arm/ of perfu- Dose (mg of Leak systemic 
no. years leg sion, min TN Fa % TNFa (ng/ml) 
1 55 F Sarcoma Leg 90 2 23 169 
2 52 F Melanoma Leg 90 4 20 178 
3 66 M Sarcoma Arm 90 3 12 30 
4 61 F Sarcoma Arm 30 3 65 277 
5 71 F Melanoma Leg 90 2 24 112 
6 56 M Sarcoma Leg 90 2 15 77 
7 65 M Melanoma Leg 90 2 32 108 
8 64 F Melanoma Leg 90 4 13 104 
9 83 M Sarcoma Leg 75 4 19 174 
10 55 F Sarcoma Leg 90 4 16 90 
Treatment schedule 
The procedure of ILP has been described previously.5 In brief, ILP consisted of a 90-
minute-long perfusion with 3 to 4 mg of recombinant human TNFa (Boehringer 
lngelheim, Alkmaar, The Netherlands) and 10 to 13 mg/liter perfusion tissue of mel-
phalan (Alkeran; Burroughs Wellcome, London, UK) at mild hyperthermia (39 to 40°C}. 
Composition of the perfusate was as follows: priming volume of 700 to 850 ml 
consisted of 400 to 500 ml of blood (50% red blood cells/50% plasma), 200 to 400 ml 
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of 5% dextran-40 in glucose 5% (Isodex, Pharmacia, Uppsala, Sweden), 10 to 30 ml of 
8.4% sodium bicarbonate and 0.5 ml of 2500 to 5000 IU heparin. TNFa was injected 
as a bolus into the arterial line provided limb tissue temperature was >38°C. Melphalan 
was administered 30 minutes later at limb temperatures between 39 to 40°C. At the end 
of perfusion, the limb was washed with at least 2 liters of 6% dextran-70 (Macrodex, 
Pharmacia). During and after ILP, vital signs of the patients, including body temperature, 
heart rate, blood pressure and fluid balance were recorded. Toxicity was registered 
according to the World Health Organization criteria. 12 
Leakage monitoring 
During ILP, there was a dynamic balance between two pressure compartments, the 
systemic vasculature and the isolated circuit, which could be influenced by adjusting the 
systemic blood pressure and/or the extracorporeal flow rate. Throughout the perfusion 
period, any potential leakage of the drugs was monitored by using a radioactive tracer. 
A small calibration dose of human serum albumin radiolabeled with iodine 131 or 
technetium 99m was injected into the systemic circulation and a 10-fold higher dose of 
the same isotope into the isolated extremity. Continuous monitoring was performed with 
a precordial scintillation probe. Systemic leakage was expressed quantitatively as a 
percentage such that 100% leakage represented a homogeneous distribution of the 
isotope in the body. 
Blood sampling procedure 
Venous blood samples were collected at several time-points, i.e., the day before ILP, just 
before administration of TNFa in the perfusate, halfway perfusion and just before release 
of the tourniquet (after completion of the washout procedure at the end of the perfusion). 
Then after ILP, 5, 10, 30 minutes and 3 and 7 hours after release of the tourniquet and 
once a day until 7 days after ILP. Samples from the perfusate were obtained at the 
following times: 0 Oust before administration of TNFa) and 10, 30, 60 and 90 minutes 
after administration of TNFa. Blood samples were immediately centrifuged; plasma was 
collected and stored at -70°C until tested. 
Assays for cytokine and acute phase protein analysis 
Cytokine and acute phase protein levels were measured by using enzyme-linked 
immunosorbent assay (ELISA). Used antibodies were obtained from the Central 
Laboratory of the Blood Transfusion Service (Amsterdam, The Netherlands). For 
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measuring TNFa, as described previously,13 flat-bottomed microtiter plates (Nunc, 
Kamstrup, Denmark) were coated overnight with purified monoclonal antibody (mAb) 
against TNFa (CLB-TNF/7). After washing serial dilutions of TNF-containing samples 
were added. Bound TNFa was detected by biotinylated sheep anti-TNFa. The detection 
limit of the assay was 5 pg/ml. Healthy controls were at less than 5 pg/ml. 
The IL-6-specific ELISA has been described previously. 14 A coat of CLB-IL-6/16 was 
applied overnight, and bound IL-6 was detected by biotinylated affinity-purified poly-
clonal sheep anti-IL-6. The lower detection limit was 1 pg/ml and normal healthy 
control subjects were at less than 10 pg/ml. 
For IL-8, a coat of CLB-IL-8/1 mAb was applied overnight and bound IL-8 was detect-
ed by biotinylated affinity-purified polyclonal sheep anti-IL-8. The lower detection limit 
of this assay was 8 pg/ml. Normal values were at less than 20 pg/ml. 15 
C-reactive protein (CRP) levels were measured by a sandwich ELISA, using polyclonal 
rabbit anti-human CRP Abs as catching Abs and biotinylated mAb anti-CRP (CLB anti-
CRP-2) as a detecting Ab. Results were referred to a standard (Behringwerke AG, 
Marburg, Germany) and expressed in mg/1. The detection limit was 10 ng/liter. 16 
The ELISA used for measuring secretory phospholipase A2 (sPLA2) has been described 
before. 17 Two different mAbs against human sPLA2 were used as coating and catching 
antibodies respectively. The lower limit of detection was 0.1 ng/ml. Normal healthy 
volunteers were at less 5 ng/ml. 
Statistics 
Median values are expressed with range. Comparison between the cytokine and acute 
phase protein levels in the two groups (with and without leakage) were made by the 
Mann-Whitney U test. Values of p s 0.05 were considered to be statistically significant. 
RESULTS 
Systemic toxicity 
Ten patients with a systemic leakage percentage of more than 10% were entered this 
study. Leakage varied from 12% to 65% (mean 24%, table 1). Because of expected 
toxicity all patients are well monitored at our intensive care unit post-operatively. 
Systemic toxicity is summarized in table 2. 
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Table 2. Systemic toxicity following ILP in the 10 patients with leakage to the systemic circulation 
compared to 9 patients without leakage 
Toxicity (WHO grade) 
Grade 0-1 Grade II Grade III GradeN 
Leakage 
Fever 2 8 0 0 
Hypotension 3 3 4 0 
Leukocytes a 8 0 1 1 
Platelets b 6 3 0 1 
Bilirubin c 3 3 4 0 
ALAT/ASAT d 7 3 0 0 
Nausea 8 2 0 0 
Non-leakage Grade 0-1 Grade II Grade III Grade IV 
Fever 6 3 0 0 
Hypotension 9 0 0 0 
Leukocytes 9 0 0 0 
Platelets 9 0 0 0 
Bilirubin 9 0 0 0 
ASAT/ALAT 9 0 0 0 
Nausea 8 1 0 0 
WHO, World Health Organization; ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase. 
a gr. III: 0-1.9 x 109/]iter; gr.N: < 1.0 x 109/]iter 
b gr. II: 50-74 x 109/]iter; gr.IV: < 25 x 109/liter 
c gr. II: 2.6-5 x N; gr. III: 5.1-10 x N (N =upper limit of normal value) 
d gr. II: 2.6-5 x N 
During ILP, blood pressure and pulse rate remained stable with adequate fluid 
management. The body-temperature did not increase above 38°C. After ILP, all patients 
received indomethacin to suppress flu-like symptoms. Eight of 10 patients developed 
fever grade II (38 to 40°C) within a few hours after ILP (mean maximal temperature 
38.9°C}. In the patients without detectable leakage the mean maximal temperature was 
38.1 °C. In 4 leakage-patients, the heart rate increased to more than 110 beats per 
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minute (range 120-132 beats per minute). Four patients had a hypotension, which was 
not quickly restored to normal values by fluid administration alone, and required addi-
tional treatment with dopamine (3-6 f-1-g/kg/min) during 2 to 3 days. From the start of 
surgery, a mean of 8 liters was administered to the leakage-patients during the first 16 
hours versus 5 liters for non-leakage patients. Leukopenia and thrombocytopenia was 
absent or mild. Grade N leukopenia and thrombocytopenia in one patient was induced 
by leakage of melphalan. No transfusion was required. Patients without leakage did not 
develop hematological toxicity. All leakage-patients had a hyperbilirubinemia after 2 days 
and the transaminases increased (grade I-11). In the no-leakage group, only 1 patient had 
a mild hyperbilirubinemia. No pulmonary or renal toxicity was observed in any patient. 
Plasma cytokine and acute phase protein levels 
In Figure 1, median values with range were represented for the cytokines TNFa and IL-
6 and the acute phase proteins (APPs) CRP and sPLA2. Median peak levels of all 
measured cytokines and APPs in both patient groups, depicted in table 3, were 
significantly different (p-values in Table 3). Because we know the curves of IL-8 and 
sPLA2 from previous published experiments'8• 19 we restricted the determinations to the 
pre-operative and the maximum level time points. 
In the leakage group, very high circulating concentrations of TNFa are found during per-
fusion (at - 45 minutes) in contrast to the non-detectable TNFa-levels in patients without 
leakage. Plateau circulating concentrations are measured at the end of the perfusion, 
lasting up to 30 minutes after ILP. The small amount of TNFa that remains in the limb 
after the washout procedure does not increase the colossal systemic levels any further in 
these patients in contrast to what is observed in patients without leakage. There we 
observed a brief peak of systemic levels more than 1 00-fold less than in leakage patients. 
Moreover, the peak occurs typically at 5-10 minutes after ILP and represents the TNFa 
that was left behind in the limb after the washout. TNF-levels decreased already after 30 
minutes, because rapid clearance of this cytokine with a short half-life time of 17 
minutes is operational. Thus, in leakage-patients very high TNF-concentrations are 
present for about 4 hours, whereas a very short peak of 20 to 30 minutes of 
"moderate" increased TNF-levels is present in leakage-free patients. There was a strict 
correlation between the degree of leakage estimated by isotope monitoring, the (adjusted) 
dose of TNFa and the measured maximum systemic levels of TNFa, depicted in table 1. 
IL-6 increased already during perfusion in leakage-patients, immediately induced by 
TNFa. In the non-leak patients IL-6 increased 5 to 10 minutes after ILP, i.e. after TNFa 
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from the washed out limb appeared in the systemic circulation. Maximum values of IL-6 
were reached 3 hours after ILP. IL-8 showed the same pattern as IL-6 (data not shown). 
In the control group, values of IL-6 and IL-8 were 10 to 60 times lower than in the 
leakage-patients. 
The APP CRP was increased from 3 hours after ILP until more than 7 days after ILP. 
Peak levels occurred at day 1. The CRP curve in patients without leakage was compa-
rable, but the peak value was higher. Levels of sPLA2 were very different for each 
patient. However, the pattern was consistent, with the start of increase at 3 hours after 
ILP and the peak at day 1. Levels were still increased after 7 days. Levels in the non-
leakage patients were factor 6 lower. 
Levels of cytokines and acute phase proteins in perfusate 
No significant difference was observed in perfusate-levels of cytokines and APPs in 
patients who underwent ILP with systemic leakage and without leakage. From the ILP-
patients with systemic leakage, only 5 series of perfusate samples were available. Curves 
are presented in figure 2. TNF levels remained stable around 7.5 ~-tg/ml. IL-6 increased 
after 10 minutes of perfusion, to 4.3 ng/ml at the end of perfusion. IL-8 increased from 
65 to 1600 pg/ml during perfusion. CRP did not change during perfusion, with values 
hardly detectable or at less than the detection limit. In 3 of 5 patients sPLA2 increased 
during perfusion; the median value at the end of perfusion was 14 ng/rnl and the range 
8.5 to 266 ng/rnl. 
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Figure 1. Median (with range) of TNF (A) and IL-6 (B) and CRP and sPLA2 (C) in plasma from 10 
patients who underwent an ILP complicated by high leakage (> 12%) to the systemic blood circula-
tion. For TNF (o; A), IL-6 (D;B) and CRP (0; C), the curves of the non-leakage group are also 
depicted. Time-points were as follows: pre, pre-operative; 0', just before perfusion; -45', halfway 
perfusion; -1 ', just before release of the tourniquet; 5' (10' and 30'), 5 (10 and 30) minutes after 
release of the tourniquet; 3h and 7h, 3 and 7 hours after ILP; d1 to d7, number of days after ILP. 
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Table 3. Median and range of peak-levels of cytokines and acute phase proteins in 10 patients under-
going ILP with more than 10% leakage compared with 9 patients without leakage in the systemic 
circulation 
Cytokine/acute Leakage-patients, No leakage, 
phase protein Time-point median (range) median (range) 
TNFa, ng/ml 10 min after ILP 108 (26-277) 1.4 (0.3-3.4) 
IL-6, ng/ml 3 hours after ILP 49 (13-257) 0.8 (0.3-3.3) 
IL-8, ng/ml 3 hours after ILP 14 (1.3-49) 0.2 (0.01-1.7) 
CRP,mg/1 Day 1 76 (34-419) 166 (93-350) 
SPI.A2, ng/ml Day 1 568 (123-986) 84 (20-390) 
A 1oo.ooo.ooo 
1.000.000 
-TNF 
10.000 -IL-6 
~ 
0.. 100 
~IL-8 
0' 10' 30' 60' 90' 
time 
B 1000 
,: :: ~:: --··r : :r:: :1 :::: t: __._CRP mg/1 
--sPLA2 
ng/rnl 
0,1 
0' 10' 30' 60' 90' 
time 
p-value 
p<0.001 
p<0.001 
p<0.001 
p<0.01 
p<O.Ol 
Figure 2. Median (with range) of cytokine (A) and acute phase protein (B) profile in perfusate from 
5 patients who underwent an ILP complicated by high leakage (> 12%) to the systemic blood circu-
lation. Time-points were as follows: 0', just before administration of TNFa in the perfusate; 10' (30' 
and 60'), 10 (30 and 60) minutes after start of perfusion; 90', end of perfusion, just before release 
of the tourniquet. 
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DISCUSSION 
The aim of our study was to quantify cytokine levels and acute phase response in patients 
who underwent an ILP with high dose TNFa complicated by high leakage, compared with 
the same variables in patients without leakage, and correlate findings with clinical 
toxicity. In this study, we measured TNFa plasma-levels up to 277 ng/ml. Nevertheless, 
most of the patients needed only extra intravenous fluid administration. Systemic levels of 
this magnitude have been described before in the same setting 20·21 and once after a 
30-min intravenous infusion of recombinant TNFa. 22 
In our patients the necessity for dopamine administration was not related to the highest 
levels of TNFa in the systemic circulation. This finding is in accordance with previous 
studies in which no correlation between maximum TNFa concentrations in the 
peripheral blood of an individual and the side-effects could be found, 20·23 which indicates 
that patients vary in their sensitivity to TNFa. 
Systemic toxicity seems to be determined by the duration of exposure to high levels of 
TNFa. Our data demonstrate this clearly, with levels of 1000 to more than 100,000 
pg/ml for 4 hours in high leakage patients, and only "moderate" levels (~1000 pg/ml for 
20 minutes) in non-leakage patients. In non-leakage patients, 20 minutes of "moderate" 
TNF-levels were not enough to cause hypotension. This is in accordance with the findings 
reported previously in this journal by Vrouenraets eta!., who described minimal toxicity 
after leakage-controlled ILP in 20 patients. 24 The IL-6 curves demonstrate the effect of 
prolonged exposure to high TNF levels even more pungently. Even at 24 hours after ILP, 
IL-6levels are still higher in the leakage-patients than the peak IL-6levels observed in ILP-
patients without leakage. IL-6 levels remained elevated for at least 3 whole days. 
In the 10 patients with high leakage, 4 hours of exposure to very high levels of TNFa 
resulted in 3 patients with grade II and in 4 patients with grade III hypotension. Four 
patients required dopamine support temporarily with good response. In phase I-II studies 
on the systemic administration of TNFa, dose-limiting toxicity was observed at TNF-
concentrations similar to those observed in our 10 patients described here. For instance, 
Schaadt et al. reported dose-limiting hypotension in 32% of the patients after admini-
stration of 650 !!g/m2 intravenously, resulting in a systemic TNF peak concentration of 
approximately 270 ng/ml. Moreover, grade II hepatotoxicity was observed in 80% of the 
patients. This is quite different from the relative lack of toxicity observed in our 10 ILP-
patients who had similar systemic TNF peak concentrations. In other studies, hypotension 
was dose-limiting at lower doses, with serum TNF levels of 10 ng/ml. 8•9 
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In comparison with septic shock, the duration of exposure to elevated levels of TNFa in 
the leakage-patients is relatively short. The prolonged exposure in septic shock, despite 
of concentrations many times lower than the short peak levels after ILP, results in the 
typically unresponsiveness of the hypotension to fluid challenge in the septic shock 
patients. zs.zs Adequate diuresis plays a key-role to keep the period of high circulating 
TNF-levels as short as possible, to prevent a septic shock-like state in perfusion patients. 
That patients are well hydrated at the time of exposure to TNF, and that their blood pres-
sure is optimally maintained by fluid challenge, and only if necessary also by the use of 
dopamine, prevents septic shock-like situation. This explains why these patients have 
little toxicity in view of the very high circulating TNF-levels. It is a fundamental difference, 
with often poorly hydrated patients with metastatic cancer who received intravenous 
TNFa in phase 1-11 studies in the past. Moreover, septic patients are infected and have 
significant levels of endotoxin, which has been shown to be synergistic with TNFa for 
toxicity (in rats).29'30 In addition Feelders eta!. have shown in patients who underwent ILP, 
cortisol is already increased before the TNF-peak as a result of surgery and anesthesia. 31 
The cortisol response may have a down-regulatory effect on TNFa. 
The increased TNFa-levels in the patients with systemic leakage were followed by signif-
icantly higher levels of IL-6 and IL-8. This is in accordance with previous studies.18•20•32 In 
our study, we also determined CRP and sPLA2 as parameters of the acute phase 
response. sPLA2 levels were more increased in the leakage-patients; CRP, in contrast, had 
significantly lower levels in these patients at the time points of maximum values. Lower 
levels of CRP than expected were also observed in patients who underwent an isolated 
hepatic perfusion.33 That CRP had even lower levels in leakage-patients could be ascribed 
to a higher expenditure of CRP in the neutralization of the effects of exposure to higher 
levels of TNFa. 34-36 
In conclusion, ILP complicated by high leakage to the systemic circulation, resulted in high 
systemic levels of TNFa up to 277 ng/ml. IL-6 and IL-8 followed with significantly 
higher levels compared with values measured in patients without leakage. The pattern of 
the APPs CRP and sPLA2 resembled each other, except that CRP levels had significantly 
lower maximum levels in leakage-patients compared with patients without leakage. 
Overall, the patients with high systemic leakage had a marked mild clinical course. It is 
our experience that, even in patients with very high leakage, life-threatening reactions 
have not occurred and that temporary hypotension can be easily dealt with by fluid 
challenge and sometimes by temporary vasopressor support. Our observations support 
the need for further study of the potential use of TNFa systemically. 
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ABSTRACT 
Background: Tumor necrosis factor- alpha (TNFa) has been found to be very effective 
in the isolated limb perfusion setting for advanced extremity tumors. In a phase I study 
of intrapleural administration of TNFa 5 patients were followed for inflammatory 
response patterns. 
Patients and methods: Malignant mesothelioma patients were treated with repeated 
intrapleural administration of 0.1-0. 2 mg recombinant TNFa. Samples of serum and 
pleural fluid were taken at different time-points before and after TNFa-administration. 
Levels of TNFa, interleukin-6 (IL-6), interleukin-8 (IL-8), C-reactive protein (CRP) and 
secretory phospholipase A2 (sPLA2) were measured using enzyme-linked immunosorbent 
assays (EUSAs). Alpha 1-acid glycoprotein (a1-AG) was measured by nephelometry. 
Results: In pleural fluid TNFa and IL-8 reached peak levels, up to 50-700 ng/ml and 
6-60 ng/rnl, respectively, 24 hours after administration of TNFa. IL-6 (peak levels up to 
250 ng/rnl) and sPLA2 peaked after 48 hours. A slower and less dramatic pattern was 
observed for the levels of CRP and a1-AG. In serum no detectable levels TNFa and IL-
8 were observed, whereas serum levels of IL-6, sPLA2 and CRP showed a clear increase 
after intrapleural administration of TNFa. Cytokines and acute phase proteins showed 
the same pattern during subsequent cycles even up to 12 cycles. Tumor regression was 
not observed. 
Conclusions: In the setting of a phase I study of repetitive intrapleural administration 
of TNFa in mesothelioma patients, we studied the characteristics of the inflammatory 
response. Intrapleural administration was followed by a clear inflammatory response 
locoregionally. In spite of TNFa peak levels as high as 700 ng/ml systemic levels were 
never detectable. The secondary cytokine response led to very high intrapleural IL-6 and 
IL-8 levels. Systemically, IL-8 levels were never detectable whereas high IL-6 levels were 
induced systemically initially, with a decreased response to each intrapleural TNFa 
administration over time. The acute phase response in contrast remained remarkably 
constant throughout the course of repeated intrapleural administrations of TNFa. 
Intrapleural administration of TNFa is well tolerated, but associated with inconsistent and 
rather moderate impact on production of pleural fluid. This can be achieved by other 
simpler and cheaper treatment, thus we see no justification for further studies. 
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INTRODUCTION 
Malignant mesothelioma is a twnor associated with exposure to asbestos. 1 Recent 
studies have indicated that the incidence of malignant mesothelioma with its long time 
between exposure and presentation of the disease will continue to rise in the future. 2 
Malignant mesothelioma is a notoriously refractory tumor to all current treatments. 
Neither surgery3 nor radiotherapl·5 results in an increased survival. The median survival 
of mesothelioma is about 10 months.4•6•7 Therefore various alternative approaches have 
been tested.8 Pleural mesothelioma tends to stay locoregionally throughout most of its 
natural course.9 This biological behaviour makes this disease amenable to locoregional 
administration of cytostatic agents or biologic agents such as interferon-gamma (IFNy)10 , 
interferon-alpha11 , IL-2Y-14 With intrapleural administration of IFNy or IL-2 antitumor 
responses have been recorded and it was speculated that TNFa might be implicated in 
these antitumor effects. Thus we decided to explore intrapleural administration of TNFa, 
a cytokine that had failed systemic administration because of excessive toxicity .15•16 
Therefore the clinical use of TNFa is restricted to locoregional application. It is already 
very successfully used in the treatment of irresectable sarcoma and melanoma. 17•18 
There are very few reports on intracavitary TNFa in humans. TNF has been adminis-
tered intraperitoneally in patients with advanced peritoneal carcinomatosis. 19·20 Regional 
toxicity (abdominal pain) instead of systemic toxicity was the dose-limiting factor in this 
setting. Intrapleural administration was studied in patients with malignant pleural effusion 
by Karck et al. 21 Treatment with up to 200 !!g/m2 weekly, led in 3 out of 6 patients to 
disappearance of effusion. Because of this preclinical and clinical data, we decided to 
perform a phase I study in patients with stage I-liA malignant pleural mesothelioma with 
TNFa to study the clinical effect on pleural mesothelioma and evaluate the inflammatory 
response after this mode of administration. 
We have shown previously that leakage of TNFa during isolated limb perfusion (ILP) 
caused an acute phase response. 22 This was demonstrated by an increase of IL-6 direct-
ly after ILP until 2 days thereafter, followed by increase of CRP, a l-AG and a!-
antitrypsin after 1 day, and decrease of negative acute phase proteins albumin and 
transferrin during ILP till 6 hours after ILP. 
In the literature it is questioned whether the acute phase protein response (APR) could 
be downregulated by a repeated stimulus. 23 Clinical studies have shown that in a number 
of chronic inflammatory diseases the APR is less than would be expected for the 
activity of inflammation.24-26 In our patients a repeated stimulus is mimicked: at regular 
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time intervals of 2 weeks, TNFa is administered. This enables us to investigate whether 
repeated administration of TNFa is still able to provoke an acute phase response. 
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PATIENTS AND METHODS 
Patients 
Five patients with pleural mesothelioma in a phase I study were sampled for evaluation 
of biologic response patterns. Demographical and clinical characteristics are summarized 
in Table 1. Staging and diagnosis of mesothelioma was based on computerized tomo-
graphic (CT) scan of the chest, thoracoscopic findings and histological examination of 
biopsy samples. According to Butchart's staging system27 stage I is defined as tumor 
confined within the capsule of the parietal pleura, i.e. involving only ipsilateral pleura, 
lung, diaphragm and external surface of the pericardium within pleural reflection. Stage 
IIA is defined as mesothelioma invading chest wall or mediastinal tissues with or without 
lymphnode involvement ipsilaterally inside the chest. 
Eligibility criteria required histologically confirmed pleural mesothelioma stage I-liA, suf-
ficient pleural effusion to insert an intrapleural catheter, no signs of loculation on the CT 
scan, no prior chemo-, radio- or immunotherapy, age < 76 years, Karnofsky perfor-
mance status ;;, 80%, no cardiovascular disease, a white blood cell count"" 4.0 x 109/1, 
platelets "" 100 x 109/1, serum bilirubin and creatinine levels within the institution's 
normal range, no active infection, no use of corticosteroids and obtained informed 
consent. The protocol was approved by the hospital's ethical committee. 
Table 1. Patient characteristics and treatment response 
Patientno. Age Sex Stage Treatment Response Response 
after 6x after 12x 
1 63 M 1x 0.1mg 
2 65 M 12 x 0.1 mg SD PD 
3 63 M liA 18 x 0.2 mg SD SD-PD 
4 65 M 6x 0.1 mg PD 
5 57 M 6x 0.1 mg PD 
Treatment schedule 
About 2 weeks before the first administration of TNFa a Port-a-cath system was surgi-
cally inserted under general anaesthesia. The correct intrapleural position was examined 
radiographically and a technetium-99m colloid scan was made to evaluate the distribution 
of pleural fluid throughout the pleural cavity. 
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Recombinant human TNFa (Boehringer Ingelheim, Germany) was administered as an 
intrapleural infusion, repeated every 14 days. Four patients were treated with a dose of 
0.1 mg, one patient with 0.2 mg. 
Tumor response evaluation 
Response was evaluated after every 6 cycles using CT scan of the chest. Turn or response 
and toxicity were assessed according to the criteria of the World Health Organization 
(1979). 28 In case of measurable disease, complete response (CR) was defined as the dis-
appearance of all known disease for at least 4 weeks; partial response (PR) as a decrease 
of >50% in tumor size for at least 4 weeks; stable disease (SD) as a decrease of <50% 
in tumor size. Progressive disease (PD) was defined as an increase of >25% in the 
diameter of any lesion or the appearance of a new lesion. 
Immunomonitoring and cytokine- and acute phase protein assays 
Both serum samples and pleural fluid were collected at 4 time-points during each cycle: 
24 hours before administration of TNFa, 24 hours and 48 hours after administration and 
at day 8. All samples were cryopreserved until testing. 
Levels of TNFa, IL-6, IL-8, CRP and sPLA2 were measured using enzyme-linked 
immunosorbent assays (ELISA). Used antibodies were obtained from the Central 
Laboratory of the Blood Transfusion Service (Amsterdam, The Netherlands). 
For measuring TNFa, as described previously29, flat-bottomed microtiter plates (Nunc, 
Kamstrup, Denmark) were coated overnight with purified monoclonal antibody (mAb) 
against TNFa (CLB-TNF/7). After washing, serial dilutions of TNF-containing samples 
were added. Bound TNFa was detected by biotinylated sheep anti-TNFa. The detection 
limit of the assay was 5 pg/ml. Healthy controls were below 5 pg/ml. 
The IL-6 specific ELISA was described previously.30 A coat of CLB-IL-6/16 was applied 
overnight and bound IL-6 was detected by biotinylated affinity-purified polyclonal sheep 
anti-IL-6. Lower detection limit was 1 pg/ml and normal healthy control subjects were 
below 10 pg/ml. 
For IL-8 a coat of CLB-IL-8/1 monoclonal antibody (mAb) was applied overnight and 
bound IL-8 was detected by biotinylated affinity-purified polyclonal sheep anti-IL-8. The 
lower detection limit of this assay was 8 pg/ml. Normal values were below 20 pg/ml. 31 
CRP levels were measured by a sandwich ELISA using polyclonal rabbit antihuman CRP 
Abs as catching Abs and biotinylated mAb anti-CRP (CLB anti-CRP-2) as a detecting 
Ab.32 Results were referred to a standard (Behringwerke AG, Marburg, Germany) and 
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expressed in mg/1. Detection limit was 10 ng/1. 
The ELISA used for measuring sPLA2 was described before.33 Two different mAbs 
against human sPLA2 were used as coating and catching Abs respectively. The lower 
limit of detection was 0.1 ng/ml. Normal healthy volunteers were below 5 ng/ml. 
Levels of a1-acid glycoprotein were measured by means of a nephelometric assay. 
Antisera were obtained from the Central Laboratory of the Blood Transfusion Service 
(Amsterdam, The Netherlands). Normal values were 400-900 mg/1. 
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RESULTS 
Cytokine and acute phase protein levels in pleural fluid 
Peak-levels (median with range) of cytokines and acute phase proteins of all patients are 
represented in Table 2. In Figure 1 measurements of the first 6 cycles of patient 2 are 
depicted, the results of the other patients were comparable. After TNF-administration the 
concentration of TNFa increased in 24 hours to levels in the range of 50 to 100 ng/ml. 
After 48 hours still some TNFa was measurable (150-500 pg/ml). No TNFa was 
measurable after 8 and 14 days. Before the first administration of TNFa IL-6 was 
increased in all patients, values varying from 1200 to 80,000 pg/ml. It rose sharply to 
100 ng/ml after 24 hours and 250 ng/ml after 48 hours. After 8 days it declined to 30-
80 ng/ml, after 14 days levels were in the range of 15-33 ng/ml. IL-8 started at 180-
260 pg/ml. It increased sharply during in the first 24 hours to 2-12 ng/ml, then it 
decreased to 0.7-1.0 ng/ml at 48 hours and about 200 pg/ml after 8 days. After 14 
days levels were around 150 pg/ml. Levels of CRP increased during the first cycle from 
3 mg/l at start to 60 mg/l after 8 days. Thereafter values remained constant around 60 
mg/1. sPLA2 increased during 48 hours from around 5 ng/ml (3-9 ng/ml after 24 hours) 
to 20-30 ng/ml. It decreased slowly over the following 2 weeks. Levels of a1-AG 
remained constant around 1300 mg/l after a slow rise from 700 mg/1. The production 
of cytokines demonstrated the same pattern even after cycle 12 in patient 2. 
Serum-cytokine and acute phase protein levels 
In serum (Figure 2, Table 2) no TNFa and no IL-8 was measurable in any patient. IL-6 
could not be detected in two patients but increased sharply in the other three, 24 hours 
after TNF-administration; values were in the range of 125-275 pg/rnl. At 48 hours it 
was still measurable in the first 4 cycles. In the course of treatment, IL-6 levels gradually 
decreased. Before the first administration of TNFa, CRP-levels in serum were elevated 
in all patients (31-300 mg/1). CRP-levels increased slowly from around 100 mg/l after 
24 hours to 500 mg/l after 48 hours. After 8 days CRP was still measurable with values 
in the range of 100 mg/1. After 14 days values were around 40 mg/1. sPLA2 was 
increased after 24 and 48 hours to about 30 ng/ml and 130 ng/ml, respectively. After 
a few cycles, sPLA2 was also measurable after 8 days: about 7 ng/rnl. Levels of a1-AG 
were elevated before administration of TNFa (1200-2000 mg/1), it increased after 24 
hours after administration to about 2500 mg/l at day 8. After 14 days it was around 
2000 mg/1. 
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Table 2. Peak values (median, range) of measured cytokines and acute phase proteins in 5 patients 
Cytokine/ Acute phase Serum Pleural fluid 
Protein Pat Time Median Range Time Median Range 
TNFa pg/ml 1* no peak <5 24h 30000 
2 no peak <5 24h 51500 48000-118000 
3 no peak <5 24h 678000 190000-1755000 
4 no peak <5 NO 
5 no peak <5 24h 2156000 218000-4395000 
IL-6 pg/ml 1 24h 160 day 8 179000 
2 24h 173 67-279 3x48h,3x24h 248000 187500-284000 
3 no peak <1 no peak 18000-142000 
4 no peak <1 NO 
5# 24h 113 91-135 24h 286000 148500-393000 
IL-8 pg/ml 1 no peak <8 24h 6300 
2 no peak <8 24h 6000 2200-12400 
3 no peak <8 24h 64400 51000-71000 
4 no peak <8 ND 
5 no peak <8 24h 186500 3500-261000 
CRP mg/1 1 48h 499 day 14 83 
2 48h 501 385-618 no peak 3-69 
3 no peak 70-223 no peak 31-81 
4 48h 276 216-446 NO 
5 48h (2x24h) 409 327-875 day 8 88 71-198 
SPLA2 ng/ml 1 48h 67 48h 23 
2 48h 131 59-142 48h 25 16-31 
3 48h 11 9-19 no peak 0.1-7 
4 48h 47 28-78 NO 
5 48h (3x24h) 87 65-174 48h 21 17-64 
a1-AG mg/1 1 day 8 2420 ND 
2 3xd8,3x48h 2350 2090-2530 no peak 740-1560 
3 no peak 1800-2610 NO 
4 48h 2440 2320-2630 ND 
5 no peak 2100-2540 no peak 740-1620 
*Only 1 cycle 
#lL -6 was measurable only during the first two cycles, thereafter it was under detection 
limit. ND: not measured 
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Figure 1. Cytokine (a) and acute phase protein (b) profile in pleural fluid during the first 6 cycles of 
intrapleural TNF-administration in patient 2. Time-points: 24 hours before administration of TNFa, 
24 hours after TNF-administration, 48 hours after, and 8 days after. Day 14 is 24 hours before the 
next gift of TNFa. 
Toxicity and tumor response 
Five male patients were treated with intrapleural infusion of TNFa. Stage I patients were 
treated with 0.1 mg and one patient with stage IIA mesothelioma was treated with 0.2 
mg. One patient received only one dose of TNFa: Because of excessive pleural effusion, 
for which the patient needed drainage of pleural fluid, complicated by a hematothorax, 
further intrapleural TNF-administration could not be pursued. The other 4 patients were 
evaluable for toxicity and tumor response as they received a minimum of 6 doses up to 
18 doses. Overall tolerance was quite good. All patients developed flu-like symptoms and 
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mild fever (38-39.3°C) during 1-2 days. Two patients had a short episode of nausea and 
vomiting. No grade III-N toxicity according to the WHO-criteria28 was observed. No 
hypotension or increase in heart rate was observed. Furthermore, intrapleural TNFa had 
no effect on number of leukocytes and thrombocytes, kreatinin and liver functions. 
None of the patients had a tumor response, only one patient showed stable disease 
during 36 weeks. Of note, once started with treatment none of the patients needed 
drainage of pleural fluid any more. In two patients dyspnea diminished obviously during 
treatment, in one patient dyspnea did not change and one patient did not have 
complaints of breathlessness. 
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Figure 2. Cytokine (a) and acute phase protein (a) profile in serum during the first 6 cycles of 
intrapleural administration of TNFa in patient 2. Time-points: 24 hours before administration of 
TNFa., 24 hours after TNF-administration, 48 hours after, and 8 days after. Day 14 is 24 hours 
before the next gift of TNFa.. 
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DISCUSSION 
In the present study the biologic effects of intrapleural administration of TNFa in patients 
with pleural mesothelioma was studied. The results of the cytokine measurements before 
administration of TNFa showed signs of an ongoing inflammatory response. This was 
also observed by others. 34•35 Before administration of TNFa, intrapleural levels of IL-6, 
IL-8, CRP, sPLA2 and al-AG were elevated. In serum we found increased levels of CRP 
and al-AG. Our measurements correspond to the observations of Nakano et al. and 
Monti et al. 34'35 The high intrapleural IL-6 levels, before the first administration of TNFa, 
appeared to be caused by production by the mesothelioma-cells. IL-6 has been shown to 
be produced by mesothelioma-cells in vitro.36•37 IL-6, produced in the pleural cavity, 
leaking to the systemic circulation, is thought to be the responsible cytokine for the induc-
tion of the APR. The mechanism of the APR has been investigated and described 
earlier, both in vitro38•39 and in vivo. 26·40•41 
Intrapleural administration of TNFa resulted in clear IL-6, CRP, sPLA2 and al-AG 
patterns in serum, with the noticeable exception for TNFa and IL-8, which never 
reached detectable levels systemically. This may be explained by soluble receptors for 
TNFa and IL-8. With respect to the IL-6 response in serum a significant increase with a 
peak after 48 hours was observed after each TNF-administration. However, the response 
diminished gradually in the course of time, most illustrative visible in patient 2 in which 
no detectable IL-6 levels were observed when TNFa had been administered more than 
9 times. This observation indicates an "exhaustion" phenomenon or a gradual build up 
of soluble IL-6 receptor levels. 
However, the acute phase response was not diminished. This may be explained by a 
direct stimulation of the acute phase response by TNFa and IL-1. 26•40 TNFa and IL-l can 
only stimulate the positive acute phase proteins. So in our study (we only determined 
positive acute phase proteins), we could not distinguish which cytokine had the most 
impact on the stimulation of the APR: IL-6 or TNFa/ IL-l. In contrast with the studies 
mentioned above2426, we could not find a downregulation of the APR, even though the 
acute phase response was already activated before the first TNF-administration. 
Administration of TNFa did increase the levels of the acute phase proteins; this indicates 
that the APR was not maximally stimulated before the first TNF-administration. 
A possible explanation for the fact we did not find a down-regulation of the APR could 
be the relatively long treatment free period of 2 weeks between the consecutive 
administrations of TNFa. 
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TNFa had no antitumor effect in these 4 mesothelioma-patients, but seemed to diminish 
pleural effusion. Reduction of pleural fluid was also described before. 21•49 The 
mechanism of this TNF-induced reduction of pleural fluid is not quite clear. Most likely, 
fluid production by mesothelioma cells is reduced. Enhanced resorption of pleural fluid is 
less likely as this mechanism would be associated with higher systemic levels of TNFa 
and other cytokines, which we did not observe. 
In conclusion, intrapleural administration of TNFa was followed by a clear inflammatory 
response locoregionally. In spite of TNFa peak levels as high as 700 ng/rnl, systemic 
levels were never detectable. The secondary cytokine response led to very high 
intrapleural IL-6 and IL-8levels. IL-8levels were never detectable in serum, whereas high 
IL-6 levels were induced systemically initially, with a decreased response to each 
intrapleural TNFa administration over time. The acute phase response in contrast 
remained remarkably constant throughout the course of repetitive intrapleural adminis-
trations of TNFa. Intrapleural administration of TNFa is well tolerated but associated 
with a rather moderate impact on production of pleural fluid. As this effect can be 
achieved by other simpler and cheaper treatment we see no justification for further 
studies. 
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ABSTRACT 
Background: Adult onset of Still's disease is characterized by very high serum ferritin 
levels, in disproportion with other acute phase proteins (APPs). Since IFNa was observed 
to cause hyperferritinaemia in 3 healthy persons without increase of other APPs, we 
hypothesized that IFNa stimulates specifically the synthesis of ferritin. To test this 
hypothesis we studied ferritin- and other APP-levels in patients treated with IFNa. 
Patients and methods: Fifteen patients treated with IFNa-2b 3-5 times a week, as 
adjuvant treatment after excision of a high-risk melanoma, were compared to 6 patients 
without adjuvant treatment (controls). Serum levels of C-reactive protein (CRP) and secre-
tory phospholipase A2 (sPLA2) were measured using enzyme-linked immunosorbent 
assay (ELISA). Levels of ferritin, alpha1-acid glycoprotein (AAG) and albumin were 
determined by nephelometry. 
Results: CRP was significantly decreased after 4 weeks (p<0.01) in the patients treated 
with IFNa compared with the non-treated patients, after 6 months of treatment it was 
still decreased although not significantly. Ferritin increased significantly in the IFNa-
treated patients: 187% of pre-treatment value after 4 weeks and 217% after half a year 
(p<0.01), while ferritin levels decreased in the non-treated patients. AAG increased sig-
nificantly in IFNa-treated patients (107, 114%) compared with the control-patients (91, 
76%) but differences were less compared with CRP and ferritin. sPLA2 had a variable 
course, while albumin remained constant within the normal range in both patient groups. 
Conclusions: IFNa induced a significant increase in ferritin, with a significant decrease 
in CRP, little increase in AAG, varying response of sPLA2 and no change in albumin. 
This finding suggests a specific role for IFNa in the synthesis or secretion of ferritin. This 
mechanism may also be involved in the marked hyperferritinaemia in adult onset of Still's 
disease. 
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INTRODUCTION 
The acute phase response (APR) is a non-specific reaction to injurious stimuli, including 
trauma, infection, malignant growth and inflammatory disorders. The main constituents 
of the APR, the acute phase proteins (APPs), are produced by hepatocytes.1 The pro-
duction of APPs is regulated by the local presence of cytokines. In the early stage of an 
inflammatory response these cytokines are released by activated monocytes and 
macrophages. From these cytokines interleukin-6 (IL-6), tumor necrosis factor-alpha 
(TNFa) and interleukin-1 (IL-l) are the major regulators of the production of APPs. 24 In 
clinical studies with patients treated with TNFa or IL-6 a strong relationship between the 
different APPs has been found. s-s A sharp increase of CRP and serurri amyloid A (SAA) 
is observed, followed by increased levels of ferritin, protease-inhibitors and the 
complement factors, respectively. 
This pattern is also seen in almost all rheumatic diseases, except for adult onset of Still's 
disease (AOSD). AOSD is the adult variant of the systemic form of juvenile arthritis. A 
marked feature of this disease is that in almost all patients very high serum ferritin levels 
are measured. 9-12 Normally a fixed correlation between CRP and ferritin is observed both 
in vitro and in vivo, with a CRP /ferritin ratio > 100 in favor of CRP. 13-15 With the high 
ferritin levels in AOSD there is dissociation between CRP and ferritin. The cause of the 
very high ferritin levels is still not known. Based on the findings of Baynes et a!. 16 who 
found that administration of interferon-alpha in 3 healthy human subjects caused hyper-
ferritinaemia, without concomitant rise of other APPs, we hypothesized a key-role for 
interferon-alpha in this phenomenon. To test this hypothesis we determined the APR in 
melanoma patients treated with IFNa. Special attention was given to ferritin, with the 
expectation that IFNa could preferentially stimulate the synthesis of ferritin. 
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PATIENTS AND METHODS 
Patients and treatment 
The first 21 patients were selected out of a cohort that participates in a phase III study 
of the European Organization for Research and Treatment of Cancer (EORTC) of the 
adjuvant treatment with interferon-alpha2b (IFNa) in patients after operative treatment 
of a very high-risk melanoma (T4NOMO-TxN1-2MO). In that study treatment with sub-
cutaneously (s.c.) administered high-intermediate dose IFNa is compared with treatment 
with low-intermediate dose IFNa and with patients without adjuvant treatment. 
Treatment with IFNa was started within 8 weeks after definitive surgical treatment. 
Treatment schedule and patient characteristics are summarized in Table 1. 
Table 1. Treatment schedule and patient characteristics. 
Group A. Group B Group C 
Treatment schedule 5 days/week 10 MU IFNa 5 days/week 10 MU IFNa Observation 
for 4 weeks, followed by for 4 weeks, followed by 
10 MU IFNa 3 days/ week 5 MU IFNa 3 days/ week 
for 1 year for 2 years 
Number of patients 7 8 6 
Mean age (range) 44 (20-61) years 42 (27-66) years 55 (26-72) years 
Sex male/ female 2/5 2/6 5/1 
Blood sampling procedure 
Venous blood samples of these patients were collected before start of the treatment with 
IFNa, 4 weeks after start of treatment (at the end of the "induction period" consisting of 
10 MU, s.c., 5 days/week in both group A and B), and 6 months later (during "mainte-
nance treatment" consisting of 10 MU of IFNa (group A) or 5 MU of IFNa (group B), 
s.c. 3 times/week). The patients in the control arm of the study (no IFNa) were 
sampled at the same time-points. Serum samples were kept frozen at -20°C until assay. 
Assays for acute phase protein analysis 
Levels of CRP and sPLA2 were determined using enzyme-linked immunosorbent assay 
(ELISA). Used antibodies (Abs) were obtained from the Central Laboratory of the Blood 
Transfusion Service (CLB, Amsterdam, The Netherlands). CRP levels were measured by 
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a sandwich EUSA using polyclonal rabbit anti-human CRP Abs as catching Abs and 
biotinylated monoclonal antibody (mAb) anti-CRP (CLB anti-CRP-2) as a detecting Ab. 17 
Results were referred to a standard (Behringwerke AG, Marburg, Germany) and 
expressed in mg/1. Detection limit was 10 ng/1. Normal values (obtained from 100 blood 
donors) were < 5 mg/1. 
The EUSA used for measuring sPLA2 was described before. 18 Two different mAbs 
against human sPLA2 were used as coating and catching Abs respectively. The lower 
limit of detection was 0.1 ng/rnl. Normal healthy volunteers were < 5 ng/ml. 
Levels of ferritin, AAG and albumin were measured by means of a nephelometric assay. 
The used antisera were also obtained from the CLB. Normal values were ferritin 20-150 
~g/1; AAG 0.4-1.3 g/1; albumin 35-55 g/1. 
Statistics 
The Mann-Whitney U test was used to compare the 2 groups depicted in Table 2. For 
comparison of the ratios of CRP and ferritin (Table 3) we used the Fisher's exact test. A 
p-value of< 0.05 was regarded as significant. 
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RESULTS 
Median values with range of all measured acute phase proteins, expressed as 
percentages of pre-treatment levels, both in IFNa-treated patients and in control-
patients, are depicted in Table 2. Since the results of the measurements in group A 
(maintenance treatment at 10 MU IFNa) and B (5 MU IFNa) were not significantly 
different, the groups were taken together. Group A+B was compared with the control-
group by calculating significance between the values after 4 weeks (end of 10 MU IFNa 
5x/wk in both groups) and 6 months (10 MU IFNa, 3x/wk in group A, 5 MU IFNa 
3x/wk in group B) in group A+B and group C. 
Table 2. Median (range) of change acute phase proteins expressed as a percentage of the pre·treat· 
ment value in high-risk melanoma-patients getting adjuvant treatment with subcutaneous IFNa., 
compared with patients without adjuvant treatment. Significance was calculated using the Mann· 
Whitney U test, comparing data of both groups after 4 weeks and 6 months. 
Group A+B Range Group C Range p-value 
CRP 
4wk 25 2-133 178 91-533 p<0.01 
ljz yr 46 3-90 82 21-500 n.s. 
Ferritin 
4wk 187 83-1269 86 56-233 n.s. 
ljz yr 217 69-417 68 40-144 p<0.01 
sPLA2 
4wk 92 23-198 71 8-111 n.s. 
ljz yr 88 26-213 59 13-132 p<O.OS 
AAG 
4wk 107 83-190 91 77-105 n.s. 
ljz yr 114 70-126 76 54-87 p<0.01 
Albumin 
4wk 93 93-100 95 92-102 n.s. 
ljz yr 105 95-107 102 100-107 n.s. 
CRP, C-reactive protein; sPLA2, secretory phospholipase A 2; AAG, a.l-acid glycoprotein. Time-
points: 4 weeks, 4 weeks after start of treatment with IFNa. (at the end of the "induction period"); 
1;2 year, 6 months later (during "maintenance treatment"). 
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CRP was significantly decreased in the patients treated with IFNa after 4 weeks. Values 
were also lower after 6 months of treatment compared to control-patients, although the 
difference was not significant. At the same time points CRP was increased in the con-
trol-group. Ferritin showed a reverse pattern: strong increase in IFN-treated patients, 
decrease in controls. AAG-levels resembled the pattern of ferritin-levels but with a less 
steep increase, respectively decrease. The higher pre-treatment values of ferritin and 
AAG in group C were not significantly increased compared with group A+B. Levels of 
sPLA2 showed a variable course in the patients of group A+B and a decrease in the 
control-patients and albumin-levels remained constant in both patient-groups. 
To avoid a wide range of all the determinations we additionally calculated the ratios of 
increase/decrease (compared to the pre-treatment value) for CRP and ferritin. With these 
ratio the relative increase/decrease was determined. In Table 3A the median (with range) 
values of the ratio are depicted and in Table 38 the results of the 2 groups were 
compared and significance was calculated. This method of representation confirmed the 
finding of a significant decrease of CRP with a concomitant increase of ferritin in the 
patients treated with IFNa compared to patients without adjuvant treatment. 
Table 3A. Median (with range) of CRP- and ferritin-ratios and relative increase. 
4 wk CRP 4wk/CRP pre Ferritin4wk/ferritinpre Ferritin ratio/CRP ratio 
A+B 0.25 (0.03-1.3) 1.7 (1.0-3.6) 8.3 (1.1-91) 
c 1.8 (0.91-5.0) 0.62 (0.48-1.0) 0.32 (0.13-1.13) 
l/2 yr CRP 1/2y/CRP pre Ferritin l/2y/ferritinpre Ferritin ratio/CRP ratio 
A+B 0.46 (0.03-9.0) 2.8 (0.69-4.2) 4.6 (0.24-32) 
c 0.91 (0.05-5.0) 0.68 (0.40-2.3) 1.3 (0.19-13) 
Table 3B. Comparison of CRP- and ferritin-ratios and relative increase between patients treated with 
IFNa and control-patients. 
4 wk CRP 4wk/CRP pre # Ferritin4wk/ferritinpre# Ferritin/CRP ratio • 
:.1 <1 :.1 <1 :.1 <1 
A+B 2 13 15 0 15 0 
c 3 1 2 2 1 3 
lf2 yr CRP1!2y/CRPpre :f: Ferritin 112y/ferritinpre# Ferritin/CRP ratio # 
:.1 <1 :.1 <1 :.2 <2 
A+B 5 10 12 3 11 4 
c 3 3 1 5 1 5 
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CRP, C-reactive protein; Time-points: pre, before start of treatment with IFNa; 4 weeks, 4 weeks 
after start of treatment (at the end of the "induction period"); 1;2 year, 6 months later (during "main-
tenance treatment").#: p<O.OS; •: p<O.Ol; :f:: not significant 
DISCUSSION 
In the present study we observed a significant increase of ferritin after 4 weeks and 6 
months in patients treated with IFNa, with a less pronounced effect on CRP, MG and 
sPLA2 and no effect on albumin. The increase of ferritin in our patients was comparable 
with the observations of Baynes et al.16 who described an increase of 170% 
(percentage of basal value) in 3 healthy human subjects after a single subcutaneous 
injection of IFNa. CRP was also measured: it remained within the normal range. 
Besides this study, describing the short-term effect of IFNa-therapy we found one case-
report describing long-term administration of IFNa. 19 In a patient with chronic hepatitis 
C and liver hemosiderosis treatment with IFNa during 24 weeks resulted in a transient 
increase of ferritin during the first 3 weeks followed by a decrease. These observations 
were in discrepancy with our findings. However, the situation in the patient of the case 
report is more complicated: before treatment his ferritin-level was 1250 !J.g/1, while in 
our patients levels of ferritin were not increased before treatment. 
In hepatitis patients the increased ferritin levels could be a reflection of the eventual 
ongoing acute phase reaction. Moreover in several studies the increase of ferritin levels 
in hepatitis patients correlated with an iron overload (tissue levels). 20·21 In that sense by 
treating the disease the balance between inflammatory reaction in the liver/ iron content 
next to the possible effect of IFNa on the postulated increase of ferritin synthesis and 
production will determine the ferritin levels in these patients. By treating hepatitis 
patients with iron chelating therapy and IFNa the serum ferritin levels decrease far more 
significant, but still the ferritin levels were reported as slight increased above the upper 
limit of normals.20 
CRP and ferritin both behave as positive acute phase proteins, as was illustrated in our 
previous studies with cancer patients who underwent isolated limb perfusion with TNFa. 6 
In our patients treated with IFNa we observed an inverse relation between both acute 
phase proteins. Our observations suggest that IFNa might preferentially stimulate syn-
thesis and/ or production of ferritin. But we realize that until now no ex-vivo experiments 
are performed which will sustain our conclusions. 
A possible factor of influence on levels of the acute phase proteins is disease activity, 
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maybe changed by treatment with IFNa. Comparison of erythrocyte sedimentation rate 
(ESR) and the number of leukocytes in treated patients and in control patients (data not 
shown) showed no significant changes. Furthermore the sex ratio in the treated group 
was different from the sex ratio in the control group. We included the first patients 
treated in this trial, so this difference was inevitable. Since we found no significant 
difference in the pre-treatment ferritin-levels between the 2 groups we accepted the 
difference in sex ratio. 
The mechanism of the increase in ferritin after administration of IFNa is still not clear. 
As the other APPs did not (or little) increase, a role for the acute phase response is not 
likely. Since an increase of hepatic enzymes was reported after IFNa therapl2-24, release 
of ferritin caused by liver damage could be an explanation for the increased serum 
ferritin levels. This mechanism was also suggested in AOSD. 25•26 In our patients 5 out of 
15 IFN-treated patients had grade I-III increase of transaminases but without concomi-
tant rise of LDH (data not shown). So release of ferritin caused by liver damage is not a 
probable explanation. Thus release of ferritin after administration of IFNa seemed to be 
provoked by a direct effect of IFNa. 
In conclusion, the results of this study showed a significant increase of ferritin without 
comparable increase of other positive APPs after administration of recombinant IFNa. 
These findings supposed a specific role for IFNa in the synthesis or secretion of ferritin. 
This phenomenon could also be involved in the extremely high levels of ferritin in adult 
onset of Still's disease. 
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Chapter 7 
7.1 Introduction 
Tumor necrosis factor-alpha (TNFo.) is a proinflammatory cytokine with a broad spec-
trum of biological activities. Its name is derived from the ability to induce tumor cell 
necrosis. Since recombinant TNFo. became available in large quantities1, many efforts 
were undertaken to make use of its antitumor effect in man. In murine tumor models 
TNFo. induced tumor necrosis with acute softening of the tumor, hemorrhagic necrosis 
and occlusion of the tumor vasculature. 2•3 These promising results led to the application 
of TNFo. in phase I!II trials in the treatment of cancer. Unfortunately, systemic adminis-
tration of TNFo. was limited by severe toxicity at very low concentrations of TNFo. with-
out evident antitumor effect. Hypotension was the dose-limiting factor. Given these find-
ings many attempts were undertaken to apply TNFo. as a local treatment. Intratumoral4'5 , 
intra-arterial6•7 and intracavitary8•9 administration had little to no antitumor effect, again 
toxicity was dose limiting. Only 1/50 to 1/20 of the dose required for antitumor effect 
in human xenograft tumor models in mice could be administered in man. 
The problem of the dose-limiting toxicity could be overcome by the isolated limb perfu-
sion (ILP) technique. The first results of ILP with TNFa in combination with melphalan 
and interferon-gamma (IFNy) were published in 1992 by Lienard and Lejeune. 10 This 
treatment resulted in a 90% complete response rate in patients with in transit metasta-
sized melanoma 10'12 in contrast to a 50% CR rate after ILP with melphalan alone. 13•14 
In locally advanced extremity soft tissue sarcomas limb salvage was achieved in 
> 80%. 15•16 The efficacy of TNFa against the drug-resistant soft tissue sarcomas has led 
to the approval of TNFa. by the European Medicine Evaluation Agency (EMEA) for its 
use in combination with melphalan. 17 
The application of TNFa in the ILP-setting enabled us to investigate the effects of short-
term exposure to TNFo. and melphalan in man. 
7.2 Effects of TNFa on white blood cell-populations and cell-function 
7.2.1 Effects of TNFa on white cell-populations 
The procedure of ILP performed in patients with locally advanced melanoma or sarco-
ma results in remarkably little toxicity in spite of transient considerable systemic levels of 
TNFa. in the first couple of hours after ILP. To get more insight in the effects of leakage 
of TNFa to the systemic circulation during ILP, we investigated changes in cell 
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population and cell function in patients who underwent ILP with TNFa and melphalan. 
We determined the number of monocytes and lymphocytes in patients undergoing ILP 
with TNFa and melphalan at several time-points during and after ILP, and compared the 
results with the same measurements in patients who underwent minor or major surgery. 
ILP with TNFa and melphalan resulted in a significant decrease in the number of mono-
cytes and a minor decrease of lymphocytes during ILP till 3 hours after ILP, followed by 
a fast restoration within one day. 18 In patients who underwent major or minor surgery 
we did not observe significant changes in numbers of monocytes of lymphocytes. So a 
confounding effect of surgery or anaesthesia on changes in cell populations could be 
excluded. 
Several reports in the literature have described the effects of intravenous administration 
of TNFa on leukocytes and subpopulations. TNFa has been shown to induce a precipi-
tous leukopenia within 30 minutes after administration. 19-21 Differentiation of the sub-
populations of leukocytes gave the following observations: Neutrophils declined within a 
few minutes, followed by a sharp increase in neutrophil counts. Monocytes also 
decreased rapidly, reaching lowest levels after 30 minutes. Lymphocytes and eosinophils 
decreased during the first 4 hours after administration of TNFa.19•20·22•23 
The initial neutropenia is most likely caused by adhesion of neutrophils to the vascular 
endothelium. In in-vitro studies TNFa was found to enhance the adherence of neu-
trophils to cultured endothelial cells. Neutrophils adhere to vascular endothelium by 
increasing the expression of the CD11/18 complex on the surface of neutrophils24"26 
and by endothelial cell adhesion molecule expression. 25•27 ICAM-1 (intercellular adhesion 
molecule-1), E-selectin and P-selectin (as endothelial cell adhesion molecules) were found 
to be involved in the TNF-induced adhesion of neutrophils to the endothelial cells. The 
expression of selectins increased with increasing concentration of TNFa. 25 
The subsequent neutrophilia consisted of increased numbers of immature neutrophils, 
suggestive of recruitment of neutrophils from the bone marrow. 28·29 Adrenalectomized 
rats that were treated with TNFa developed the same pattern of neutropenia and neu-
trophilia, indicating that TNFa did not mediate its hematologic effects via the release of 
adrenal hormones. 29 
Molecular mechanisms of monocyte adhesion are less well understood. Several endothe-
lial cell adhesion molecules (VCAM-1, vascular cell adhesion molecule-1; ICAM-1) and 
monocyte integrins (LFA-1, lymphocyte function antigen-1 (CDlla/CD18); Mac-1, 
CD1lb/CD18; VLA-4, very late antigen-1) had been shown to be involved.30-32 The 
TNFa-induced lymphopenia and eosinophil adhesion is also based on an interaction of 
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surface-proteins on lymphocytes and endothelial cells. 33-36 A clear difference was found 
between T-cell and neutrophil adhesion to TNF-stimulated endothelial cells in in vitro 
adhesion assays: Adhesiveness of neutrophils increased rapidly within 4 hours, while 
adhesiveness forT-cells was smaller and more gradual.37 
The rapid onset of induction of adhesion molecules on endothelial cells and integrins on 
leukocytes pointed out a direct effect of TNFa. Nevertheless influence of other media-
tors, for instance other cytokines, induced by TNFa can not be excluded. 
The activation of endothelial cells by TNFa is not specific for tumor microvasculature. 
Activated endothelial cells were also found in normal vessels after exposition to 
TNFa. 38•39 Activation of tumor endothelial cells leads to overexpression of adhesion mol-
ecules, followed by invasion of polymorphonuclear cells and possibly lymphocytes and 
macrophages, endothelium injury, and coagulative and haemorrhagic necrosis.40·41 In 
normal tissue the upregulation of adhesion molecules was not followed by polymor-
phonuclear cell invasion and necrosis. The underlying mechanism of this difference 
between tumor endothelial cells and normal tissue endothelial cells is still under investi-
gation. A possible role is ascribed to integrin aV~3, which is expressed by endothelial 
cells during formation of new blood cells, but nor by resting endothelial cells. RUegg et 
al. demonstrated that TNFa and IFNy could inhibit aV~3. This resulted in disruption of 
endothelium in the tumor vasculature. 42 
Both in ILP-patients and in patients treated with TNFa intravenously TNFa induced a 
fast disappearance from the systemic circulation of all types of leukocytes, by inducing 
adhesion to the endothelial cells. This mechanism plays an important part in the migra-
tion of cells into sites of inflammation. 
7.2.2 Effects of TNFa on cell function 
Cell function in our patients was determined by measuring production of cytokines after 
stimulation in whole blood cell culture (WBCC). For monocyte-function TNFa and IL-6 
were determined after stimulation with lipopolysaccharide. In patients treated with ILP 
we found a significant decrease in cytokine-production which started already before the 
administration of TNFa (possibly caused by haemodilution). Cytokine production 
remained significantly diminished until day 1. In patients who underweht major surgery 
we observed also a decrease in cytokine production which started during operation. 
However, the reached nadirs were higher compared to the levels in ILP-patients, and the 
cytokine production was restored within one day. After minor surgery and in healthy 
controls no fluctuations in cytokine production were observed.43 
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Lymphocyte-function was determined by measurement of IL-8 production after whole-
blood stimulation with anti-CD3/anti-CD28. In an additional study we tried to distinguish 
between T-helper-1 (Th1) and T-helper-2 (Th2) cells, by measuring intracellular levels of 
IFNy (produced by Th1-cells) and IL-4 (produced by Th2-cells) after stimulation in a cul-
ture of peripheral blood mononuclear cells. We also measured IFNy, IL-2 (Th1) and IL-4 
(Th2) after stimulation in WBCC. 
In ILP-patients and in patients who underwent major surgery we observed a decrease in 
cytokine-production from the end of the operation until day 1. After minor surgery and 
in healthy controls we observed no change in cytokine-production. 18 Intracellular 
staining of cytokine production showed a decrease in IFNy-producing cells, from the 
time-point of administration of TNFa into the perfusate until 3 hours after ILP. The 
fraction of IL-4-staining cells was too small to measure fluctuations during and after ILP.43 
Our in-vivo findings are quite different from observations made in in vitro systems: 
cytokine-production in monocyte cultures in response to lipopolysaccharide (LPS) could 
be augmented by TNFa.44'45 Similarly, as was found for monocytes, TNFa also enhanced 
in vitro production of cytokines by T-lymphocytes.4648 
A decreased monocyte and lymphocyte function was found in patients after intravenous 
administration of TNFa.49'5° Furthermore, in patients after major surgery51.53 and during 
sepsis54•55 downregulation of cytokine production by monocytes and lymphocytes had 
been described. 
For explanation of the monocyte-deactivation several hypotheses have been suggested: 
Tissue injury by itself is certainly the key factor in immunodepression and altered 
cytokine .production after surgery. This is supported by the observations that patients 
with extensive burns56 and patients with multiple accidental injuries57•58 also have severe 
immunosuppression, manifested in depressed in vitro cytokine production by monocytes. 
Tissue injury leads to activation of macrophages and production of proinflammatory 
mediators. This local inflammatory reaction is supposed to induce several cascades result-
ing in monocyte deactivation. 
First, local or systemic inflammation .leads to activation of the stress response, expressed 
by corticosteroids and catecholamines. These stress hormones induce an upregulation of 
IL-10.59 IL-10 was demonstrated in vitro to be a potent macrophage-deactivating 
cytokine.60.62 Also in vivo IL-10 was found to play a key-role in the several mechanisms 
of immunosuppression in patients with septic shock63 and in patients undergoing major 
abdominal surgery. 64 
During inflammation TNFa by itself can induce IL-10 mRNA as well, and in combination 
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with other stimuli (like low-dose LPS or prostaglandins) it can also induce IL-l 0 protein 
synthesis, leading to monocyte deactivation. 59 In this way inflammation may trigger its 
own downregulation. 
A third hypothesis is based on the finding that uptake of apoptotic material by 
macrophages inhibits the release of inflammatory cytokines by human macrophages. 65-67 
Massive induction of apoptosis (e.g. in organ failure in septic and trauma patients) can 
thus result in a downregulation of TNF secretion capacity and upregulation of IL-10 
secretion. 59 
Table 1. Mechanisms of monocyte-deactivation in patients treated with TNFa 
1. Stress-response (corticosteroids and catecholamines) induces IL-10 
2. TNFa induces IL-10 
3. Massive uptake of apoptotic material by monocytes upregulates IL -10 secretion 
The biological function of the endotoxin hyporesponsiveness can be assumed to be pro-
tection against excessive inflammatory response. This results in an increased risk to 
develop sepsis and multiple organ failure in patients with affected monocyte function. 51•68 
As was found in our ILP-patients a downregulation ofT-cell cytokine-production was also 
demonstrated in patients undergoing various types of trauma such as surgery or burn 
injury and in patients with septic shock. Major surgery69-71 , trauma72 and severe sepsis73 
decreased the number of T-helper cells and induced a shift in the T-helper 1/ T-helper 
2 (Thl(fh2) balance toward Th2, caused by decrease of Thl-cells. Besides decrease of 
the number of T-helper cells also the cytokine-production of the remaining cells after in 
vitro stimulation was diminished.70'71 '74 This suppression of cellular immunity was found 
to be caused by hypersecretion of catecholamines, cortisol and other adrenal corti-
costeroids. Also overproduction of immunosuppressive acidic protein and other acute 
phase reactants69•75·76 and production of PGE2 from activated monocytes/ 
macrophages77•78 has been reported to result in diminished T-cell cytokineproduction. 
Since TNFa is a known inducer of cortisol23•79 , PGE280"82 and the acute phase response, 
the mechanisms mentioned above can also be involved in the immunosuppression 
following TNF-administration. 
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Table 2. Mechanisms of impairment of lymphocyte function in patients treated with TNFa 
1. Stress-response (corticosteroids and catecholamines) 
2. Production of immunosuppressive acidic protein and other APPs 
3. PGE2, produced by activated monocytes 
Exposure to TNFa in ILP-patients was shown to induce a transient impairment in mono-
cyte and lymphocyte function. Comparable observations have been made in patients 
who underwent major surgery or patients during sepsis. Several causal factors had been 
hypothesized in the mechanism of this immunosuppression. Since cancer patients and 
non-cancer patients peri- and postoperative are especially in need of their immune 
system against respectively growth and metastasis of residual tumor cells and post-
operative infections immunosuppression must be prevented as much as possible. In the 
future it may be possible to intervene in the mechanism of immunosuppression with 
biological response modifiers to reduce the incidence of postoperative-complications. 
7.3 TNFa and the acute phase response 
7.3.1 The acute phase response after ILP 
TNFa is one of the inflammation-associated cytokines that are involved in the regulation 
of acute phase protein (APP) synthesis. Interleukin-6 (IL-6) and IL-6 type cytokines are 
the chief stimulators of the acute phase response by stimulating the full spectrum of acute 
phase proteins, both upregulation of positive APPs and downregulation of negative 
APPs. TNFa as well as interleukin 1 (IL-l) (together IL-l type cytokines) have only effect 
on a subset of positive APPs83.85 and negative APPs. 86 This classification is based on in 
vitro studies. 
In our patient groups we could determine the specific role of TNFa as a stimulator of the 
acute phase response (APR) in vivo. Our observations in the systemic circulation of 
patients undergoing an ILP had the following results: high systemic levels of TNFa 
directly after ILP induced a rapid increase of IL-6 and IL-8. C-reactive protein (CRP), 
secretory phospholipase A2 (sPLA2), al-acid glycoprotein (AAG) and al-anti-trypsin 
(AAT), complement components C3 and C4 started to increase 3 hours after the end of 
ILP. The highest levels of CRP and sPLA2 were obtained 1-2 days after ILP. The serum 
levels of the other APPs increased more slowly and modestly and reached their highest 
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level at day 3. All investigated proteins declined after they had reached their peak levels, 
except for C3 and C4 which both remained elevated for at least 4 days. The negative 
APPs, albumin and transferrin decreased to a minimum of 60% of their initial value at 
10 minutes after ILP. The recovery was very slow; albumin did not reach its initial value 
within 7 days. 87.89 Most observations were done in patients who underwent an ILP with-
out systemic leakage during the perfusion. We also performed some determinations in 
patients who underwent an ILP with high systemic leakage (12-65% leakage). High sys-
temic levels of TNFa resulted in ten- to more than hundredfold increased levels of TNFa, 
IL-6 and IL-8. The increase of the levels of the APPs CRP and sPLA2 was less pro-
nounced; CRP-levels were even lower compared to the levels in patients without 
leakage. 
As already mentioned above, the patients with high systemic leakage had a marked mild 
clinical course. The temporary hypotension could be easily dealt with by fluid challenge 
and sometimes by temporary vasopressor support. This relative lack of toxicity can be 
explained by the short duration of exposure to elevated levels of TNFa in comparison 
with septic shock. Moreover, septic patients are infected and have significant levels of 
endotoxin, which has been shown to be synergistic with TNFa for toxicity. Adequate 
diuresis is very important to keep the high circulating TNF levels as short as possible. 
This is a fundamental difference with the often poorly hydrated patients with metastatic 
cancer who received intravenous TNFa in phase I-II studies in the past. Finally, a pro-
tection mechanism was found in the soluble TNF receptors, which are shown to buffer 
the bioactivity of TNFa. 90 
Most likely the observed alterations in acute phase protein levels reflect the fluctuations 
in the synthesis of the APPs by the liver, induced by the activated cytokine network. In 
vitro, TNFa stimulates the synthesis of various positive APPs (AAG, serum amyloid A 
(SAA), CRP, C3) and decreases synthesis of the negative APPs albumin and transferrin 
in human hepatoma and rat hepatoma cell culture. 91-93 In rodents, administration of 
TNFa resulted in increase of SAA, serum amyloid P (SAP), C3, AAG and fibrino-
gen. 92·94'97 The effect of TNFa was found to be mediated by the type I TNF receptor 
(p55); 91,98 
Although these findings correspond largely to our results in humans we have to realize 
that the in vivo situation is much more complex, since in vivo hepatocytes are exposed 
to a sequence and combination of interacting cytokines and other mediators. 99 
In the in vitro and in vivo findings mentioned above besides type 1 APPs (induced by IL-
l type cytokines) some type 2 APPs (induced by IL-6 type cytokines) are mentioned. Also 
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in our ILP-patients we found an increase in AAT, which is a type 2 APP. This indicates 
that we can not clearly distinguish the separate effect of TNFa on the measured acute 
phase protein levels, because of the rapid induction of other cytokines. 
From our observations in the patients with high leakage of TNFa in the systemic circu-
lation it can be suggested that acute phase proteins can not be stimulated above a cer-
tain level. This was also found in patients who underwent an isolated hepatic perfusion 
for irresectable colorectal liver metastases. 100 To our knowledge this phenomenon has 
not been described in other clinical studies. However a reduction in CRP-levels had been 
well observed in malnourished patients who underwent a major abdominal operation, 
without a concomitant reduction in other APPs (AAG, AAT).101•102 Also in rats receiving 
a protein deficient diet the magnitude and time profile of levels alpha2-macroglobin and 
albumin was attenuated. 103•104 Taking together these findings it can be concluded that 
particularly for CRP there is evidence that production seemed to be limited, probably 
caused by a shortage of protein-elements in the liver. 
Our observations in the ILP-patients have yielded some more insight in the role of TNFa 
in the stimulation of the APR. ILP with TNFa and melphalan in patients with melanoma 
or sarcoma resulted in a rapid increase of many positive APPs and decrease of negative 
APPs. From data of patients with high systemic leakage it can be concluded that levels 
of APPs have a limited range. 
7.3.2 The acute phase response during repeated/chronic stimulation 
The preceding studies describe the acute phase response after a relative short-term 
exposure to TNFa. Since until now little is known about the conversion of the acute 
phase response to chronic inflammation we wanted to study a clinical model with long-
term administration of TNFa in patients. A phase I trial in which patients with malignant 
mesothelioma were treated with repeated intrapleural administration of TNFa presented 
the opportunity to study this question. 
Every 2 weeks administration of TNFa in the pleural cavity resulted in a locoregional 
cytokine- (TNF, IL-6, IL-8) and APP- (CRP, sPLA2, AAG) response. In pleural fluid TNFa 
was measurable for more than 48 hours. IL-6, IL-8, CRP and AAG remained elevated 
till the next administration of TNFa. In serum no detectable levels of TNFa and IL-8 
could be measured. IL-6 was elevated during more than 48 hours, although the magni-
tude of the values decreased after every TNF-injection. The decreasing response of IL-6 
was accompanied by a clear and stable acute phase response. 105 
Normally the APR subsides over 24-48 hours and within a few more days the organism 
returns to normal function. However, when the stimulus persists, the normal pathway is 
prolonged and the APR is supposed to be converted in a chronic phase of inflammation. 
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Several studies have been performed and reported on in the literature to get more insight 
in the mechanism of the continuation of the APR in chronic inflammation: Long-term 
culture of human hepatocytes or hepatoma cells resulted in a clear APR after exposure 
to IL-6. Peak-levels were reached within 2-4 days, followed by stabilization. After removal 
of the stimulus levels of APPs returned to pretreatment values within 5 days. 106-108 
Discrimination between acute and chronic inflammation in rodents and cattle was possi-
ble by measurement of different levels of elevated APPs: in cattle a differentiation could 
made in level of SAA and haptoglobin. 109 In mice concentration of AAG- and albumin 
mRNA were specifically different in acute and chronic inflammation. 110 After prolonged 
inflammation induced by intraperitoneal injections with turpentine, lipopolysaccharide 
and celite an initial increase of APP mRNA was followed after about 2 days by a 
gradual decline to a new baseline after 5 days. 110 A diminished APR after recurrent 
sterile inflammation in mice could not be demonstrated by Todd et al.lll They suggested 
that the phenomenon of low APR in several chronic or recurrent inflammatory diseases 
in man may not simply result from chronic inflammation itself but may be part of a 
predisposition to chronic inflammation. 
Clinical studies describing the APR in recurrent or chronic inflammatory diseases are far 
from unanimous. Some studies described a diminished APR (a discrepancy between 
cytokine-levels and levels of APPs) in multiple myeloma-patients112, cachectic patients 
with pancreatic cancer113 and in cancer-patients treated with subcutaneous IL-6. 114 Other 
studies did not observe a clear decrease in the levels of APPs in patients with advanced 
pancreatic cancer115, in cancer-patients treated with subcutaneous recombinant human 
IL-6116 and in patients with unstable angina pectoris. 117 
The fact that we did not find a downregulation of the acute phase response is maybe due 
to the relatively long time (14 days) between the consecutive administrations of TNFa. 
Since cytokines have a short half life and are only in circulation at important levels for a 
short time, the time between two successive cytokine-administrations is required to be 
within a few days. Nevertheless it is astonishing that comparable clinical studies resulted 
in such different observations as described above. This indicates that the APR is a com-
plex system with multiple interactions between cytokines and APPs. 
From our observations in patients who were treated with intrapleural administration of 
TNFa it can be concluded that repeated exposure to TNFa evoked a clear locoregional 
and systemic cytokine- and acute phase response. We did not observe a down-regulation 
of the APR in these patients in spite of the repeated inflammatory stimuli. 
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7.3.3 IFNa and the acute phase response 
IFNa is known for its antiviral activity and its role in the treatment of malignancies. 118-120 
Furthermore several clinical studies described induction of cytokines by IFNa. 121·122 Only 
a few studies had investigated the relation of IFNa to the acute phase response. 
Administration of lFNa in cancer patients had no effect on serum cytokines and APPs 
(CRP, AAG) in a study of Israel et al. 123 Bir6 et al. described the response of the acute 
phase complement component to IFNa in patients with chronic hepatitis C.124 In these 
patients the complement system was already activated before treatment and when 
administration of IFNa was started the intensity of activation decreased in both 
responders and non-responders. However only in the responder patients did this 
decrease result in an increase of serum concentration of complement proteins C9 and 
Cl-inhibitor. So in these patients it seems IFNa has an indirect effect on the APPs, by 
influencing disease-activity. 
Ferritin is a known acute phase protein, which is also involved in the iron-
metabolism.125-127 Patients with adult onset of Still's disease (AOSD) are characterized by 
very high-elevated ferritin-levels. Also levels of other APPs are increased, but ferritin 
levels are much higher in AOSD than in inflammatory diseases. 128-130 The origin of the 
great amount of serum ferritin in AOSD is still unknown. Levels of the cytokines TNFa 
and IL-6 are found to be increased in patients with active AOSD. 131·132 However this 
does not explain why ferritin is much more elevated than other APPs. An indication was 
found in observations in persons treated with subcutaneous administration of IFNa. In 
these persons a significant increase of ferritin was observed without a concomitant 
elevation of CRP. 133 Based on these findings we hypothesized a specific role for IFNa in 
the induction of hyperferritinaemia. To test this hypothesis we determined several levels 
of APPs in patients with high-risk melanoma during treatment with subcutaneously 
administered IFNa. 134 In these patients we observed indeed a significant increase in 
ferritin, accompanied with a significant decrease in CRP and little or no change in the 
other APPs. There was no difference between the effect of a dose of 5 MU IFNa and 
10 MU IFNa. 
The mechanism of the specific induction of ferritin by IFNa is still unknown. From our 
findings it was concluded that most possibly there must be a direct effect of IFNa on the 
synthesis or secretion of ferritin. Release of ferritin as participant in the APR could be 
excluded since other APP-levels showed little or no alteration. Also liver damage as a 
cause of hyperferritinaemia is less probable since only 5 out of 15 patients had grade 
I-III increase of transaminases, without concomitant elevation of LDH. 
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IFNa elicits its antiviral and imrnunoregulatory activities by binding to specific receptors 
on the cell surface. 118' 135'136 These receptors are present on several cells, like monocytes, 
lymphocytes and hepatocytes. 136'137 The binding of IFNa to the cell surface receptor ini-
tiates signals that are transmitted from the cell surface via a complex pathway to the 
nucleus118•138 , resulting in multiple biological activities mediated by IFNa. A possible 
explanation of the increased ferritin in our patients could be the stimulation of secretion 
or synthesis of ferritin mediated by this system, since ferritin is also known to be present 
in the liver and in monocytes. 126•139 
Most possibly the increase of ferritin in patients treated with IFNa without a clear APR 
is direct effect of IFNa. 
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Figure 1. Schematic representation of the effects of TNFa leading to tumor necrosis, and the inter-
action with the cytokine- and acute phase response. 
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7.4 Conclusion 
Recombinant TNFa has made a successful return in the clinic because of its application 
in the setting of isolated limb perfusion. This enabled us to get more insight in the 
properties of TNFa in humans. We have summarized the current knowledge about the 
in vitro and in vivo effects of TNFa on monocytes and lymphocytes and the acute phase 
response, with the emphasis on the effects in humans. In patients treated with 
intravenous TNFa and in patients undergoing ILP with TNFa and melphalan a rapid and 
precipitous leucopenia was induced. Differentiation resulted in a rapid decrease of 
neutrophils and monocytes and a slower decline of lymphocytes and eosinophils. 
Monocyte- and lymphocyte-function, expressed as ex vivo stimulated cytokine produc-
tion, decreased within a few hours. Administration of TNFa was followed by a clear acute 
phase response, probably induced in co-operation with IL-6. Repeated exposure to 
TNFa resulted in a continuous APR without down-regulation. In figure 1 our findings are 
represented in a flow diagram. 
With the obtained skills and knowledge we ended with a study of the APR in response 
to administration of IFNa. We observed a preferential increase of ferritin, with only a 
slight increase or no response of other positive APPs and no response of negative APPs. 
These findings support our hypothesis that IFNa is implicated in the hyperferritinaemia 
in adult onset of Still's disease. More study is needed to confirm these findings and to get 
more insight in the mechanism. 
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SUMMARY 
During isolated limb perfusion with TNFa and melphalan, patients are exposed to high 
concentrations of these drugs in the perfused limb and low concentrations in the systemic 
circulation. The clinical application of this technique, in the treatment of locally advanced 
melanoma and sarcoma, made it possible to study the immunomodulatory effects of 
exposure to TNFa and melphalan in man. Effects of longterm exposure to cytokines 
were investigated in mesothelioma-patients treated with intrapleural TNFa and 
melanoma-patients treated with subcutaneous IFNa. 
In chapter 1 an overview is given of the history of and present developments in the appli-
cation of TNFa, the acute phase response and treatment with IFNa. 
The antitumor effect of TNFa was demonstrated to be mainly mediated by specific 
destruction of tumor vessels resulting in hemorrhagic necrosis. Clinical application 
systemic administration of TNFa has been hampered by doselimiting toxicity already at 
doses too low to mediate antitumor effects. Only with isolated limb perfusion adequate 
doses of TNFa can be achieved with minimal and easily manageable systemic 
side-effects. Besides its effects on endothelial cells TNFa is a known stimulator of the 
acute phase response. In in-vitro studies TNFa was found to induce a specific subgroup 
of acute phase proteins, called type I acute phase proteins. The in-vivo situation is more 
complex because of interaction with other cytokines and other mediators. Chapter 1 
ends with a paragraph about the interaction of IFNa with other cytokines and acute 
phase proteins. 
In chapter 2 the cytokine-response and effects on monocyte- and lymphocyte number 
and function were investigated in patients who underwent isolated limb perfusion with 
TNFa and melphalan. The same parameters were measured in patients after minor and 
major surgery and in healthy controls. Release of TNFa from the tissues in the perfused 
limb after ILP resulted in systemic peak levels immediately after ILP, followed by an 
increase in IL-6. TNFa was not measurable in the other patient groups. IL-6 reached 
detectable levels during major surgery, but lower peak-levels than in the ILP-patients. No 
IL-6 could be detected after minor surgery and in healthy controls. The number of mono-
cytes and lymphocytes showed a sharp decline in ILP-patients, which was interpreted as 
a sign of the margination effect of TNF on leukocytes. In surgical patients and healthy 
controls no significant change in monocytes or lymphocytes took place. Furthermore 
138 
Summary and conclusions 
production of cytokines after stimulation in whole blood cell culture (WBCC) was inves-
tigated. Both in ILP-patients and major surgery patients cytokine production by stimu-
lated monocytes in WBCC was completely depressed at 3 hours after operation. At day 
1 the function was almost restored. In minor surgery patients and in healthy controls 
cytokine-production did not change significantly. The same pattern was observed for 
cytokine-production by T-lymphocytes. These results showed a tremendous effect of 
TNFa on cell-number and cell-function in terms of highly significant differences in 
cytokine patterns in ILP-patients and also in patients who underwent major surgery. 
In chapter 3 the effects of TNFa on number and function of T-cells in ILP-patients were 
studied in more detail and were further specified. Moreover, effects were differentiated 
by making a differentiation in T-helper 1 (Th1) and T-helper 2 (Th2) cells. The number 
of T-cells declined sharply to 5% of the pre-operative value at 3 hours after ILP. Both 
intracytoplasmic production of cytokines after cell stimulation and cytokine production 
after stimulation in WBCC showed a decrease in cytokine-levels which started during ILP 
to hardly measurable levels at 3 hours after ILP. Th 1-related cytokines were equally 
diminished as Th2-related cytokines. In this study no specific relation of TNFa to either 
Th1-cells or Th2-cells could be demonstrated. 
In chapter 4 patients with significant leakage of TNF from the perfusion circuit into the 
systemic compartment were investigated. Systemic toxicity in these patients was studied 
in detail after an ILP with leakage to the systemic circulation of 12-65%, and was com-
pared to the clinical course in patients without leakage. Additionally cytokine- and acute 
phase levels were measured in both groups. 
The most prominent clinical toxicity was hypotension, grade III in four patients. This was 
easily corrected with fluid administration and if necessary dopamine. Hematological 
toxicity was mild and no renal or pulmonary toxicity was observed. TNFa reached levels 
up to 277 ng/ml in leakage-patients. Also IL-6 and IL-8 were significantly higher in 
patients with high systemic leakage. Maximum sPLA2-levels were higher in the leakage-
patients whereas levels of CRP were lower, suggestive for higher expenditure of CRP in 
the removal of injured cells. ILP complicated with high leakage to the systemic circula-
tion is accompanied by manageable toxicity and an elevated cytokine- and acute phase 
protein response. 
After above-mentioned investigation of the inflammatory response of a single exposure 
to TNFa in chapter 5 the effects of repeated administration of TNFa were examined. 
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From patients with malignant mesothelioma treated in a phase I trial with intrapleural 
administration of TNFa every 2 weeks both serum and pleural levels of cytokines and 
acute phase proteins were determined. The treatment was well tolerated. In pleural fluid 
administration of TNFa provoked a clear cytokine- and acute phase response with the 
same pattern after each infusion. In spite of intrapleural TNFa-levels up to 700 ng/ml 
serum-levels of TNFa and IL-8 remained under detection-level. High IL-6 levels were 
induced systemically, but with a decreasing response after each intrapleural administra-
tion of TNFa. The acute phase response was not diminished: the same pattern of 
increase, followed by decrease of levels of CRP, sPLA2 and al-acid glycoprotein 
remained constant after every administration of TNFa. 
Repeated intrapleural administration of TNFa resulted in a clear locoregional and 
systemic inflammatory response. 
The finding that IFNa induced ferritin without elevation of other acute phase proteins, 
and the resemblance of this patterns with findings in patients with adult onset of Still's 
disease (AOSD) is elaborated in chapter 6. Patients with high-risk melanoma were 
treated after excision with subcutaneously administered IFNa 3-5 times a week in a 
phase III-trial. 
Levels of acute phase proteins were determined in serum before treatment and after 4 
weeks and half a year during treatment. IFNa induced a significant increase in ferritin-
levels without a comparable increase of other positive acute phase proteins. These results 
confirmed our hypothesis that the high ferritin-levels in patients with AOSD may be a 
direct effect of IFNa. 
In chapter 7 the results of the presented studies are integrated and discussed. 
140 
Summary and conclusions 
Conclusions made on the basis of the studies are: 
• ILP with TNFa and melphalan results in a tremendous decrease in cell-number and 
function of monocytes and lymphocytes. 
• Major surgery has less effect on cell-number but results in a similar almost completely 
depressed cell-function after operation. 
• A specific effect of TNFa on T-helper 1 or T- helper 2 cells can not be demonstrated: 
both types of T-lymphocytes are completely depressed in number and function after 
ILP. 
• High leakage of TNFa to the systemic circulation during ILP results in manageable 
toxicity and a clear cytokine- and acute phase response 
• Repeated intrapleural administration of TNFa induces a clear locoregional and 
systemic cytokine- and acute phase response 
• IFNa has a direct effect on synthesis or secretion of ferritin, without affecting other 
acute phase proteins 
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Chapter 8 
SAMENVATTING 
Tijdens geYsoleerde extremiteitsperfusie met tumor necrose factor-alpha (TNFa) en 
melfalan worden patienten blootgesteld aan hoge concentraties van deze middelen in de 
geperfundeerde extremiteit en !age concentraties in de systemische circulatie. De 
klinische toepassing van deze techniek, in de behandeling van lokaal vergevorderd 
(irresectabel) melanoom of sarcoom, maakt het mogelijk om de immuun-modulerende 
effecten van blootstelling aan TNFa en melfalan in patienten te bestuderen. De effecten 
van langdurige blootstelling aan cytokines werd onderzocht in patienten met een 
mesothelioom, die werden behandeld met intrapleuraal toegediend TNFa en in patien-
ten met een melanoom die werden behandeld met subcutaan toegediend interferon-
alpha (IFNa). 
In hoofdstuk 1 wordt een overzicht gegeven van de geschiedenis van en de huidige 
ontwikkelingen in de toepassing van TNFa, de acute fase reactie en behandeling met 
IFNa. 
Het anti-tumor effect van TNFa blijkt met name te worden veroorzaakt door specifieke 
destructie van tumorbloedvaten resulterend in hemorrhagische necrose. Bij klinische 
toepassing van TNFa wordt _systemische toediening van TNFa bemoeilijkt door dosis-
limiterende toxiciteit, reeds bij doseringen die te laag zijn om anti-tumor effect te 
bewerkstelligen. Aileen met geYsoleerde extremiteitsperfusie kan een adequate dosis 
TNFa bereikt worden met minimale en goed behandelbare systemische bijwerkingen. 
Naast bovengenoemde effecten op de tumorbloedvaten heeft TNFa een stimulerend 
effect op de acute fase reactie. In vitro studies Iaten zien dat TNFa een specifieke 
subgroep van acute fase eiwitten stimuleert, de zogeheten type I acute fase eiwitten. 
De situatie in vivo is complexer vanwege interactie met andere cytokines en andere 
stoffen. Hoofdstuk 1 wordt afgesloten met een paragraaf over de interactie van IFNa met 
andere cytokines en acute fase eiwitten. 
In hoofdstuk 2 worden de cytokine-respons en de effecten op monocyten- en 
lymfocyten- aantal en -functie bestudeerd in patienten die zijn behandeld met een 
geYsoleerde extremiteitsperfusie (ILP) met TNFa en melfalan. In patienten die een kleine 
operatie (extremiteit) of een buikoperatie ondergingen en in gezonde personen werden 
dezelfde parameters bepaald. Afgifte van TNFa uit de weefsels in de geperfundeerde 
extremiteit na ILP resulteerde in systemische piekwaarden onmiddellijk na ILP, gevolgd 
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door een stijging in IL-6-waarden. In de andere patientgroepen was TNFa niet meetbaar. 
IL-6 bereikte meetbare waarden tijdens en na abdominale chirurgie, maar lagere piek-
waarden dan in de ILP-patienten. Na een kleine operatie en in gezonde proefpersonen 
kwam IL-6 niet boven de detectiegrens. Het aantal monocyten en lymfocyten daalde 
scherp in de perfusie-patienten. Dit wordt toegeschreven aan het effect van TNFa op de 
bloedvaten, waardoor leukocyten aan de endotheelcellen hechten. In chirurgische patien-
ten en gezonde proefpersonen traden geen significante veranderingen op in het aantal 
monocyten en lymfocyten. Ook de cytokine-produktie na stimulatie in volbloedcelkweek 
werd onderzocht, als maat voor celfunctie. Zowel in perfusie-patienten als in de 
patienten die abdominale chirurgie ondergingen was 3 uur na de operatie de cytokine-
produktie door monocyten na stimulatie in volbloedcelkweek volledig onderdrukt. 
De volgende ochtend was de cytokine-produktie weer vrijwel geheel hersteld. In patien-
ten die werden behandeld met een kleine chirurgische ingreep en in de gezonde 
controle-personen werden geen significante veranderingen gezien in de cytokine-
produktie door monocyten. Hetzelfde patroon als hier beschreven voor monocyten werd 
gevonden in cytokine-produktie door T-lymfocyten. Kort samengevat laat deze studie 
zien dat TNFa een aanzienlijk effect heeft op cel-aantal en -functie, zich uitend in grate 
schommelingen in cytokine-produktie in perfusie-patienten en in patienten behandeld 
met abdominale chirurgie. 
In hoofdstuk 3 worden de specifieke effecten van TNFa op het aantal en de functie van 
T-lymfocyten meer in detail beschreven voor een groep patienten die een ge'isoleerde 
extremiteitsperfusie hebben ondergaan. Daarbij wordt een onderverdeling gemaakt naar 
effecten van T-helper 1 en T-helper 2 cellen. Het aantal T-cellen daalde snel naar 5% 
van de pre-operatieve waarde op het tijdstip 3 uur na perfusie. De cytokine-produktie na 
stimulatie (als maat voor de T-celfunctie) werd op 2 manieren gemeten: in het cyto-
plasma en in volbloedcelkweek. Beide methoden toonden een scherpe daling in cytokine-
produktie, die al startle tijdens de perfusie. Drie uur na perfusie waren er nauwelijks 
cytokines meetbaar. Er was geen verschil in patroon tussen T-helper 1 en T-helper 2 
gerelateerde cytokines. Met dit onderzoek kan dan ook geen specifiek effect van TNFa 
op T-helper 1 cellen of T-helper 2 cellen worden aangetoond. 
In hoofdstuk 4 zijn perfusie-patienten met significante lekkage van TNFa van de perfusie-
circulatie naar de systemische circulatie onderwerp van studie. Systemische toxiciteit in 
deze patienten wordt gedetailleerd beschreven. De lekkage-percentages in de onder-
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zochte groep patienten varieerden van 12 tot 65%. De toxiciteit werd vergeleken met 
het klinische beloop in patienten die een perfusie ondergingen zonder meetbare lekkage. 
Ook werd in beide groepen het beloop van cytokines en acute fase eiwitten bepaald. 
De meest prominente bijwerking was hypotensie, graad 3 in vier patienten. Deze !age 
tensies waren echter vrij eenvoudig te corrigeren met extra infuus en zo nodig dopamine. 
Hematologische toxiciteit was mild en er was geen nier- of long-gerelateerde toxiciteit. 
TNFa bereikte waarden tot 277 ng/ml in patienten met systemische lekkage. Ook IL-6 
en IL-8 waren in deze patienten significant hoger dan in de patienten zonder lekkage. 
De maximale waarden van het acute fase eiwit sPLA2 waren hoger in de lekkage-
patienten in vergelijking met de patienten zonder lekkage. CRP-waarden waren echter 
lager in de patientengroep met lekkage, waarschijnlijk wijzend op een hoger verbruik van 
CRP bij het opruimen van beschadigde cellen. Concluderend gaat ge"isoleerde extremi-
teitsperfusie met TNFa, gecompliceerd door veellekkage naar de systemische circulatie, 
gepaard met behandelbare toxiciteit en een verhoogde cytokine- en acute fase respons. 
Na bovengenoemde studies naar de ontstekingsrespons van een eenmalige blootstelling 
aan TNFa wordt in hoofdstuk 5 het effect van herhaaldelijke toediening van TNFa 
bestudeerd. In patienten met een mesothelioom, die werden behandeld in een fase I 
studie met intrapleurale toediening van TNFa om de week, werden serum en pleurale 
concentraties van cytokines en acute fase eiwitten bepaald. De behandeling werd goed 
verdragen. Toediening van TNFa leidde tot een duidelijke cytokine- en acute fase reac-
tie in pleuravocht, met eenzelfde patroon na elke toediening. Ondanks hoge intrapleurale 
TNFa-concentraties tot 700 ng/ml bleven TNFa en IL-8 in serum onder de detec-
tiegrens. IL-6 bereikte wei meetbare waarden in serum, maar deze waarden werden 
steeds lager na elke toediening van TNFa. De acute fase respons verminderde niet: het-
zelfde patroon van een initiele stijging, gevolgd door een geleidelijke daling, werd 
gevolgd door CRP, sPLA2 en a 1-zure glycoprote"ine. Dit patroon bleef zich herhalen na 
elke toediening van TNFa. Uit deze studie blijkt dat herhaalde toediening van TNFa 
resulteert in een duidelijke locoregionale en systemische ontstekingsreactie. 
In hoofdstuk 6 wordt de waarneming uitgewerkt dat IFNa ferritine induceert zonder 
stijging in andere acute fase eiwitten. Dit patroon blijkt overeen te komen met bevin-
dingen in patienten met adult onset of Still's disease (AOSD). Patienten met een hoog 
risico melanoom werden na excisie behandeld in een fase III-studie met subcutane toe-
diening van IFNa drie tot vijf keer per week. De concentraties van acute fase eiwitten 
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werden bepaald in het serum van deze patienten voorafgaand aan de behandeling, na 4 
weken en na een half jaar tijdens behandeling. Behandeling met IFNa induceerde een 
significante stijging in ferritine-concentraties, zonder een vergelijkbare stijging van andere 
positieve acute fase eiwitten. Deze resultaten bevestigen onze hypothese dat de hoge 
ferritine-spiegels in patienten met AOSD een direct effect van IFNa kan zijn. 
In hoofdstuk 7 worden de resultaten van bovengenoemde studies in hun onderlinge 
samenhang besproken. 
Op basis van deze studies kunnen de volgende conclusies worden getrokken: 
• Ge"isoleerde extremiteitsperfusie met TNFa en melfalan induceert een zeer forse 
daling van zowel het aantal als de functie van monocyten en lymfocyten. 
• Abdominale chirurgie heeft minder effect op het aantal cellen, maar resulteert in een 
zelfde vrijwel volledig onderdrukte celfunctie na de operatie. 
• Een specifiek effect van TNFa op T-helper 1 of T-helper 2 cellen kan niet worden 
aangetoond: beide typen T-lymfocyten worden qua aantal en functie volledig 
onderdrukt na ge"isoleerde extremiteitsperfusie. 
• Vee! lekkage van TNFa naar de systemische circulatie tijdens ge·isoleerde 
extremiteitsperfusie gaat gepaard met een behandelbare toxiciteit en een duidelijke 
cytokine- en acute fase respons. 
• Herhaalde intrapleurale toediening van TNFa induceert een duidelijke locoregionale 
en systemische cytokine- en acute fase respons. 
• IFNa heeft een direct effect op de synthese of secretie van ferritine, zonder andere 
acute fase eiwitten te be"invloeden. 
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